Links Site1 Links Site 2 Links Site3 Links Site4

XPOVIO (selinexor) is made by Karyopharm Therapeutics (Nasdaq: KPTI) "A couple of patients went into complete remission. For a small molecule to be able to eradicate the tumor so completely is mind-boggling and quite impressive. Moreover this is an orally administered drug that makes it very easy for patients to take it at home. Moreover, the side-effect profile is also impressive. It has no organ toxicity, no cardiac toxicity, no liver toxicity, renal toxicity, no neuropathy..." Sundar Jagannath, MD, a professor of medicine, hematology, and medical oncology at The Tisch Cancer Institute, Mount Sinai Hospital


  • Commercial-stage, global pharmaceutical company with multiple FDA approvals for various oncology indications and multiple additional drug candidates in clinical development.

  • Industry leader in targeting nuclear export dysregulation as a mechanism to treat cancer.

  • On top of Barclay's list as potential acquisition target at about $60/share.

  • Several analysts predict blockbuster sales.

  • Over 80% institutional interest

  • Analysts are very optimistic. HC Wainwright & Co. reiterated coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $26.00 (Aug 6 2021), Morgan Stanley with a $29 target, and so on. Future should be very bright for this company.

  • Numerous upcoming catalysts

Latest Corporate Presentation (August 5, 2021)


  • Morgan Stanley: Overweight. Price Target: $29

  • HC Wainwright: Buy. Price Target: $26

  • Baird: Outperform. Price Target: $17

UPCOMING CATALYSTS for KPTI in remainder of 2021

  • Continue to enhance commercial capabilities; continue to increase U.S. XPOVIO sales

  • Initiation of Phase 3 study evaluating XPOVIO + pomalidomide in patients with multiple myeloma

  • SIENDO Phase 3 top-line data announced

  • Initiation of key late-stage clinical studies in MDS, NSCLC, myelofibrosis, and CRC5.

  • Additional combination data in hematologic and solid tumor malignancies with XPOVIO and other standard of care anti-cancer drugs to be presented at ESMO 2021 (September) and other medical meetings

  • Host investor day to outline strategic imperative and pipeline priorities

  • Surprise buyout announcement very possible.


  • Pfizer - PFE

  • Gilead - GILD

  • Merck - MRK

  • Vertex - VRTX

  • Takeda - TAK

  • Bristol Myers Squibb - BMY

25 Sep 2021 -- Pfizer Karyopharm Agilent

25 Sep 2021 -- Chief Medical Office Open Market Purchase - $200,000 in KPTI stock

In May this year the Chief Medical Officer bought over $200,000 worth of KPTI in the open market. Says a lot about his confidence in the science, the company and the stock.

24 Sep 2021 -- Email blasting Karyopharm about their past management's shareholder unfriendly attitude, CFO, etc.

Second complaint filed with FINRA for pre-/Aug-5 manipulation of KPTI by the guy who bought the 7.5 puts and made a million dollars with help from a major broker. Now they've been buying 7.5 calls. Filing ID: 5659748

I'm doing Mr. Mano's job, again, because the company seems clueless about how to protect itself (shareholder value) as judged by its past inaction and its shareholder-unfriendly culture. Shareholders are just viewed as ATM machines and once money is raised, it's spending time and shareholders are to be ignored. And when there's an investor conference, CFO apparently DREADS IT!! Oh no, those damn shareholders. Let's block their emails, they're just a nuisance. FORGETTING that in a public company officers are accountable to shareholders and are there to build shareholder value, and as such, a little people skills, relationship skills, communication skills goes a long way, MR. MASON!!

I'm dreading that the new IR director is going to be reporting to you! What a hypocrisy. IR is all about relationship management, people skills, sales skills. Look at how you present yourself. In the second conference (Baird), look at your shirt and the way you wore it -- this was not a "casual business day" -- maybe buy the classic "DRESS TO SUCCESS" -- but these things should come intuitively to a CFO who needs to be building bridges with institutional and large retail shareholders (we lost a big chunk of them), and be a SALESMAN. When you meet with shareholders you need to SELL THE COMPANY and not act as though you dread being there, HELLO!

The shorts love companies that turn the other cheek and don't raise an eyebrow when attacked. Sharon and Michael on the conference call in August sighed in disappointment on the air when they saw the stock price. That's when you don't have SHAREHOLDER VALUE in the forefront of your mind.

Richard is trying to change things but I can't emphasize enough the role of institutional habit / conditioning. This Shareholder Unfriendly culture is a habit and these habits linger. Look at Mr. Mason -- supposes big chief of IR -- and look at his behavior. In the most important investor conference he didn't smile ONCE! and jittery distractive uncomfortable moves throughout that was a killer for the messaging. He looked angry and a "fuck you" attitude which is what the company has done to shareholders before Richard's time -- and I'm afraid Richard has left the IR to the same gang who got us into this hole: Mr. Mason, Mr. Mano -- and they were both hired by Dr. Kauffman. Surprise!

"My theory is that A players hire people even better than themselves. It’s clear, though, that B players hire C players so they can feel superior to them, and C players hire D players. If you start hiring B players, expect what Steve [Jobs] called ‘the bozo explosion’ to happen in your organization."- Guy Kawasaki, Chief Evangelist, Apple

That's what we have -- Dr. K, a great doctor and genius scientist and excellent human -- but a D player CEO. Look at the consequence.

I trust your decisions Richard -- we only have a 300 feet view :-)

Best Regards



Regarding Mike Mason, someone wrote: "I was thinking exactly the same, all that fidgeting made me think he didn't want to be there or he was out of his depth being there."

I analyzed and elaborated on his behavior and fact he went to a low-rated school, and no endorsements on Linkedin... may be a good CFO but doesn't seem to be a right fit for Karyopharm at this stage of our growth.


$KPTI Using this link:

Please fill out an abuse report with FINRA and ask them to investigate options/stock manipulation of KPTI leading to the 5 Aug 2021 crash which was preceded by a hug purchase of 7.50 put options and subsequent profiting about a million dollars from that trade when they crashed the stock with help with an analyst who was very bullish on the stock and called the drug a potential blockbuster a few months before but radically changed his tune to help the short sellers and put buyers, because he's ultra pessimistic outlook was absolutely unjustified, and when he had to cover the upside potential he put the SIENDO trial in tiny footnote to downplay its huge potential. One big scam. And investors were victims. And even more if you were forced to sell due to margin call or stop loss order.

I've helped FINRA before. They have a lot of power. Demand that they look to see who the put seller was, and their association with the analyst.


I filed a new abuse report with FINRA for pre-/Aug-5 manipulation of KPTI by the guy who bought the 7.5 puts and made a million dollars with help from a major broker. Now they've been buying 7.5 calls.

Submission Success Your form was submitted to FINRA successfully. Please print this form now if you wish to retain a copy for your records.

Filing ID: 5659748 (Please retain this number for further inquiries regarding this form)

Submitted Date: Thu Sep 23 17:52:43 EDT 2021


A large shareholder did this today and the stock took off!!

Move your shares not just from Type 2 to Type 1 but open a CASH account (no margin agreement) and move your KPTI shares to that account. Some brokers, even if you have the shares in type-1 (cash), as long as it's the same account, they can loan it to shorts. Having your shares in a fully cash (no margin) account, puts a nice pressure on shorts to cover and gives a nice upward push to the stock price. Do it!

Recent conferences

Morgan Stanley



Dr. Due Diligence / Reddit

Good info:


RBC Capital, Bloomberg, Barclay's and others have called Karyopharm a buyout candidate. Talk on Wall Street is that one of the following companies will be the lucky one to buy out Karyopharm ($KPTI). Which one will win Karyopharm's heart / life-saving safe drug?

  • Pfizer - PFE

  • Gilead - GILD

  • Merck - MRK

  • Vertex - VRTX

  • Takeda - TAK

  • Bristol Myers Squibb - BMY

- $2-$4 Billion is a reasonable buyout price (share price: $26 to $52 per share). With solid SIENDO solid tumor results, 6B is possible ($78).

Pfizer - PFE - 22 billion cash

Bristol Myers Squibb - BMY - 14 billion cash

Merck - MRK - 9 billion cash

AMGEN - AMGN - 8 billion cash

Gilead - GILD - 7 billion cash

Vertex - VRTX - 7 billion cash

Takeda - TAK - 6.2 billion cash

Notes from some friends / KPTI investors :

-- This is very cheap for any BP. Even a 2.2B BO would put us at $30 a share from my rough calculation.

-- Patent expirations of drugs XPOVIO (selinexor) is used in combination with to treat Multiple Myeloma and increase progression-free survival (PFS) and overall response rate (ORR) $TAK VELCADE (bortezomib) 2022 $BMY REVLIMID (lenalidomide) 2022 $BMY POMALYST (pomalidomide) 2024 $AMGN KYPROLIS (carfilzomib) 2027

-- BMY: I think that they’ve struggled with the Celgene and Myok acquisitions that they are going to take it slow for awhile and enter into more collaborations than full on acquisitions. On the flip side, I know they have struggled with Opdivo sales compared to Keytruda so the acquisition of a drug that enhances Keytruda’s utility in certain cancers would make sense for them.

-- Any of them could find value at $2-4B buy price. Maybe BMY, $PFE could rationalize $6-8B based on how they could fill and commercialize their pipeline. But KPTI is still uncovering value while expanding their “portfolio in a pill” towards more cancer targets. So difficult to say where they will be even a year from now.

-- It’s reassuring that Richard has two investor meetings on Monday and one on Tuesday, with the first one with HC Wainwright being a “podium presentation” — I assume they will be discussing KRAS data from the ESMO presentations being released on the same day! ... I have 270K plus shares! I really want a price over $20.00–which is an aggregate sale price of $1.5B?


Talking with a fellow KPTI investor about our cost basis. He wrote: "In one day all the red can go away. Just had this happen with TRIL. And guess where the gains went :) Averaged KPTI down enough to bring cost avg to $10."

That's right. I've seen that happen too in biotech, multiple times. Doubles and triples and more, in a snap.


"you need to educate yourself more in this space if you’re an investor. SIGN study showed a PFS of 2.9 months I believe but that was in heavily pretreated patients. SIENDO study is in patients responding to chemotherapy so not as heavily pretreated. The Primary endpoint is HAzard Ratio of 0.6. This by itself means there must be a significant advantage over the placebo arm for the trial to be successful. In terms of toxicity, you have to compare with PARP inhibitors (the existing maintenance treatment for ovarian cancer patients). Much worse toxicity than selinexor and parp inhibitors are dominant treatment with well over $1B in sales. I agree no guarantee trial will be successful but if HR endpoint is met, blockbuster potential here."

"I agree. SIGN PFS of 2.9 months, different patient group (worse imo), and a comparison of PARPis use/success - an area I helped form doing some of the first research on it.

I'm guessing you have never worked in biotech or in the clinic on trial. If a chemo agent is vs a placebo without combination the PIs at the sites can usually tell and you hear back about it (informally), especially at this point in regards to PFS at high recruiting sites."

"There's a lot to the company's future than Siendo results, and no analyst has given much value to that data including Morgan Stanley's $29 target. So downside is very limited. We're already under the downside due to the criminal manipulation of Aug 5."

7 PM EST Friday Night New Job Posting - SIENDO data is coming soon!!!!


1 million shorted shares were covered during the criminal manipulation of the stock in August. Loooong way to go for shorts to cover. The longer they wait the harder it gets to cover without a big loss

Of larger companies potentially looking to make a deal, Abrahams mentioned Vertex Pharmaceuticals Inc. and Gilead Sciences Inc. And among companies seen as possible targets in the biotech space due to valuation and pipeline opportunities are 89bio Inc., Karuna Therapeutics Inc., Karyopharm Therapeutics Inc.

So we have the following possible suiters:

Pfizer - PFE

Gilead - GILD

Merck - MRK

Vertex - VRTX

Takeda - TAK

Bristol Myers Squibb - BMY

Notice BMY and TAK are listed as sponsors along with Karyopharm, of the International Myeloma Foundation / Blood Cancer Awareness month.


$KPTI Phase 2 data was very good with 114 patients. SIENDO is double-blind so the company may not yet know the results, but it will find out before the public. Hiring people in anticipation of good results is BAU.

The company and its partners are feeling strong about the results. For good reasons. They're planning on the results being positive. I read one partner is already planning launch in solid tumor space.

The chief medical officer bought a ton of stock in the open marke not long ago (at much higher price than today's price). A huge sign of confidence by someone who knows this space almost better than anybody.

In terms of the stock, I don't think bad results will impact the stock much since none of the analysts are assigning any significant value but they're all saying positive data will be huge, and the stock is a third of its fair value without SIENDO data, due to criminal manipulation. I am very optimistic about SIENDO results and KPTI future with or without it.


Selinexor, an oral XPO1 inhibitor, demonstrated single-agent activity in ovarian, endometrial, and cervical cancers.

Selinexor demonstrated single-agent activity and disease control in patients with heavily pretreated ovarian and endometrial cancers. Side effects were a function of dose level and treatment frequency, similar to previous reports, reversible and mitigated with supportive care.

114 patients with ovarian (N = 66), endometrial (N = 23) or cervical (N = 25) cancer were enrolled.

7 Sep 2021 -- 3 conferences next week; data expected this month; huge solid tumor data as early as in 3 weeks.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate in the following virtual investor conferences in September:

H.C. Wainwright 23rd Annual Global Investment Conference

Format: Podium presentation

Date: Monday, September 13, 2021

Time: 7:00 AM Eastern Time

Morgan Stanley 19th Annual Global Healthcare Conference

Format: Fireside chat

Date: Monday, September 13, 2021

Time: 11:00 AM Eastern Time

Baird 2021 Global Healthcare Conference

Format: Fireside chat

Date: Tuesday, September 14, 2021

Time: 2:00 PM Eastern Time

A live webcast of the fireside chats and a replay of the H.C. Wainwright presentation can be accessed under "Events & Presentations" in the Investor section of the Company's website, A replay of the webcasts will be archived on the Company's website for 30 days following the presentation and fireside chats.


  • Morgan Stanley: Overweight $29

  • HC Wainwright: Buy rating. Price Target: $26

  • Baird: Outperform rating. Price Target: $17

Move your shares to Cash account (Type 1) if they're in Margin account (Type 2) -- and do NOT day-trade KPTI

I had some shares in a margin account. I moved them to type cash account. One phone call to broker takes care of it. Highly recommended. Shares in cash account can't be loaned out to shorts, hypothecated etc. -- so it. It forces shorts who are borrowing your shares, often without your knowledge, to have to cover and it helps the stock go up. Just Do It!

As a rule of thumb, if you're a shareholder in KPTI do NOT day-trade it. If you want to trade, trade other stocks. KPTI, buy and hold it, preferably in a cash account. When you trade, that volume and volatility helps the shorts. Just Don't Do It!

New Video on Biotech by KPTI founder

Very informative talk about biotech industry by KPTI's ex-CEO, founder, current board member, scientific advisor, Dr. Michael Kauffman (MD, PhD): -- "We just came back from a week-long trip to Italy meeting -- we were in 10 different hospitals -- executives of Karyopharm including myself as Board member and medical advisor". -- one investor I respect speculates Menarini may be the European partner. I speculate there won't be a European partner before a buyout so the acquirer of $KPTI, be it Pfizer PFE, Gilead GILD or Merck MRK, will take care of Europe.

"Don't Sell Under $27"

Various investors' comments

  • An algo appeared to be buying $KPTI blocks over time Friday so as to minimally impact share price. Someone is taking a position or covering, maybe anticipating more buying coming into ESMO. Will look for this pattern buying to repeat this week, and hopefully reverse the trend we’ve been in all year. I would not consider selling under $27. $KPTI raised over $170M at $24/share in March 2020 and the pipeline prospects are better than ever!

  • maybe this research just published will make it to a late breaking poster for ESMO.

  • added last week and today. Looking forward to KRAS clinical data.

  • $XBI -invoked discount . Added 9K shares.

  • Ok, I’m back in 20,000 shares at 5.65 Would’ve bought in sooner but needed confirmation of the XBI bottom. We have it and KPTI should roll higher. See you 20+

  • For now, I’m all in at $KPTI.

  • One can never underestimate the power of fear in the stock market. The shorts really dished out extreme fear in KPTI to take the price near its all time low. The recent low at 4.42 is a re-test of the all time low at 3.92. 3.92 reflected the maximum risk--a binary outcome before the first FDA approval. But it's not dead. At 4.42 low point, KPTI has three FDA approvals, making about 100M/year, plus all the APAC development.

  • you know what they say, cut your losses and let your winners run. this is definitely one of my winners

31 Aug 2021 -- Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status

29 August - Selinexor Cured Cancer With Excellent Safety Profile

Selinexor is a 10-billion dollar medicine, and Big Pharma knows it.

Great video on how great Selinexor is:

Dr. Jagannath on the Efficacy and Safety Profile of Selinexor in Multiple Myeloma

"A couple of patients went into complete remission. For a small molecule to be able to eradicate the tumor so completely is mind-boggling and quite impressive. Moreover this is an orally administered drug that makes it very easy for patients to take it at home. Moreover, the side-effect profile is also impressive. It has no organ toxicity, no cardiac toxicity, no liver toxicity, renal toxicity, no neuropathy..." Sundar Jagannath, MD, a professor of medicine, hematology, and medical oncology at The Tisch Cancer Institute, Mount Sinai Hospital

XPOVIO (selinexor) is made by Karyopharm Therapeutics (Nasdaq: KPTI)

28 Aug 2021 -- Upcoming ESMO

One person wrote: "Upcoming ESMO abstract titles are not published yet. Those are old as phase 1 data for those was shared recently at ASCO. That being said, at 23 minutes into the Canacord call with the CEO he said they submitted presentations on NSCLC and CRC for ESMO 2021 and they are very excited about it… abstracts will be available Sept 13, I think "

What shows now:

  • 476P - Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor (SEL) and pembrolizumab (pembro) in colorectal cancer (CRC)

  • 1331P - Open-label phase 1/2 study evaluating the tolerability and anti-tumor activity of selinexor (SEL) and docetaxel (DTX) in non-small cell lung cancer (NSCLC)


Sel unique MOA could be very synergistic in solid tumors w/ Chkpt and older chemo. Stay tuned!

It looks like RAS mutations could be a biomarker for Sel in CRC.

Another person wrote; Those are the actual poster titles. They are not at the ESMO website but at the link below for attendees. I think the data from these are previously unpublished and were used to justify the latest trials for CRC and NSCLC.

Aug 2021 -- Dr. Gasparetto Rocks (2 Videos) "Selinexor is a new backbone! It is clear that the combination is effective. Average progression-free survival was 15 months for all patients. We were very pleased with the results. We had patients remaining on the therapy for a prolonged period of time because of the [good] tolerability."

Interesting presentation by Cristina Gasparetto. She is discussing the results of Phase 2 STOMP trial in multiple myeloma, particularly, two combinations, XKd and XPd. In the end of her talk she said "Even though combinations are not approved by FDA, they are highly recommended by NCCN guidelines because of favorable results".

Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Heavily Pretreated Multiple Myeloma

In this video: Dr. Cristina Gasparetto (Duke Medical Center, Durham, NC) discusses the results of once weekly Xpovio (selinexor), Kyprolis (carfilzomib), and dexamethasone (XKd) in heavily pretreated multiple myeloma. Conclusions: In patients with heavily pretreated MM, weekly XKd is highly active with an overall response rate (ORR) of 78% and deep responses (≥Very Good Partial Response 48%) with an overall progression-free survival of 23 months. All adverse events including grade 3/4 thrombocytopenia can be managed with appropriate supportive care and dose modifications. These data support further investigation of XKd in patients with previously treated multiple myeloma including those previously treated with dara. In most cases, captions are autogenerated by YouTube. _______________ Improving Lives | Finding the Cure In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.


Once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractory multipl...

"Selinexor is a new backbone! It is clear that the combination is effective. Average progression-free survival was 15 months for all patients. We were very pleased with the results. We had patients remaining on the therapy for a prolonged period of time because of the [good] tolerability."

Prof Cristina Gasparetto speaks to ecancer about the efficacy of once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractory multiple myeloma (MM) patients. Initially, she explains the background of this study. Prof Gasparetto then talks about the methodology and key results of this study. In patients with heavily pretreated MM, weekly XKd is highly active with an ORR of 78% and deep responses (≥VGPR 48%) with an overall PFS of 23 months. All AEs, including grade 3/4 thrombocytopenia, can be managed with appropriate supportive care and dose modifications. These data support further investigation of XKd in patients with previously treated MM including those with prior daratumumab treatment. In the end, she discusses the impact the results from this study can have on the future treatment of multiple myeloma

Aug 2021 -- Karyopharm one out of four potential M&A targets for Gilead, according to Bloomberg’s Marc Engelsgjerd.

28 Aug 2021 -- 2nd FINRA Complaint Directly With The Big Boss

Second complaint filed with FINRA with the chief of the options regulations team whom I know and have collaborated with before, about the recent blatant manipulation of KPTI shares and options with alleged help from one or two analysts.

Also, wrote to Mike Mano:

Dear Mr. Mano

Have you filed a formal complaint with SEC and FINRA for the blatant manipulation of KPTI stock and options in the recent halving of the price and associated hugely profitable options trade that couldn't have happened without help from one or two analysts?

Investors can't do the company's job. Company standing up for itself is far more effective. Or are you of the ultra-passive Kauffman style that turned the other cheek every time, and that's how we got into this hole? That includes online defamation which the company falsely believed was not actionable. This and other past management shortcomings contributed directly to catastrophic erosion of shareholder value. What are you doing about it? If you've filed a complaint send me the number. A lot of people lost a lot of money, and the company's valued has been halved. So if you have done nothing about it, and you absolutely could have -- at least by filing regulatory complaints -- then I suggest you look for another job.


Reza Ganjavi, MBA

28 Aug 2021 -- ESMO Preview

ESMO 2021 poster titles linked below. The related data that supported ongoing trials could be promising.


28 Aug 2021 -- MM could soar in the next years due to crazy levels of microwave RF-EMF pollution.

Sorry to say but with EMF pollution through the roof cases of MM could skyrocket in the years ahead. Safety standards totally ignore biological impact and are only thermal based. Here's one of several items lining MM to EMF pollution -- this one is for very low frequency EMF. Today we're exposed to thousands of times faster EMF.

27 Aug 2021 -- Karyopharm's Selinexor Kicks The Daylight Out of Cancer Cells

Preprint published today with findings on how Selinexor has a strong synergetic lethal effect on KRAS-mutated cancer cells that promises to be especially effective in combination therapies.

27 Aug 2021 -- SKd on STOMP trial - Patient who was not responding to other treatments is almost in complete remission from SKd

In this video, Elise shares how she landed in a cancer treatment clinical trial of selinexor + carfilzomib + dexamethasone

26 Aug 2021 -- Potential Merck, Pfizer, Gilead Bidding War For KPTI

A fried who is very experienced professionally in pharma M&A and is well connected shared with me his opinion (it should not be counted on as substantiated fact): "I think KPTI is deliberating slowing down the EMA approval process (delaying to 1H 2022) to give themselves the best shot to sell the entire company by year end. They will be in a stronger position to sell with SIENDO results plus any other positive NSCLC or CRC data showing KRAS efficacy to be shared next month.

I hear Merck and Pfizer are on the hunt for deals given their lackluster pipelines. We know Gilead is or was already looking at KPTI. "

We know Pfizer has a board member at Karyopharm. Pfizer seems to like to have a hand in the companies it later acquires. Interesting times ahead.

25 AUG 2022 -- KPTI Bashers With Potential Conflict of Interest And Link To Hedge Fund Shorts

25 AUG 2022 -- Complaint Filed FINRA about crooks who've been manipulating KPTI stock and options

Filed complaint with FINRA for abusive options trade, manipulation, collusion and conspiracy that drove the shares down, with specific info on abusive trades in KPTI. FINRA will put it under microscope. They rock. I've worked with them before and they kicked manipulators' ass before.

Filing ID: 5613105

Submitted Date: Tue Aug 24 17:17:57 EDT 2021

25 AUG 2021 Karyopharm (KPTI) is one out of four potential M&A targets for Gilead, according to Bloomberg’s Marc Engelsgjerd.

Glad to see that. However looks like Bloomberg Info is not accounting for China MM, DLBCL, and 750K+ newly diagnosed NSCLC patients/year. Also, as trial info is not published yet, not including efficacy with KRAS-mutant solid tumors and possible combination treatments. Lots of other great info including patient population stats, sales projections, and more in the Antengene HK Exchange Application Proof-

24 AUG 2022 -- Cost manageable for payers

According to the results of a study published in ClinicoEconomics and Outcomes Research, the introduction of selinexor, bortezomib, and dexamethasone (XVd) for the treatment of patients with previously treated multiple myeloma (MM) presents a manageable budget impact for a private third-party payer and Medicare in the US.

24 AUG 2022 -- 20 KPTI GOODIES

  1. Eleonora Goldberg, PhD, SVP of Global Medical & Scientific Affairs "The appointment of Eleonora Goldberg for me is another indication that the company is being turned around. The fact that she accepted the job, after having worked 10y at Amgem and was only promoted there 3 months ago, indicates to me that the future is bright. She must have been provided with some insight into the results of the trials as you don’t leave a job for a company which is going downhill…"

  2. Two doctors wrote to me: "Thanks! Could be a rewarding end of the year for KPTI!", "hi reza, i bought some shares of karyopharm today at 5 dollars a share. I agree that the price of the stock is too low compared to its future value. steven vig 8 13 2021"

  3. "My friend is good friends with the hc wainwright analyst. Said he was bullish about the company"

  4. Antengene/Karyopharm's Phase II selinexor study OK'd in China for myelofibrosis (MF). MF is a clonal bone narrow neoplasm primarily characterized by fibrosis in the bone marrow, extramedullary hematopoiesis, anemia, splenomegaly, constitutional symptoms, and possible progression to leukemia.

  5. "They have 240M cash on hand and making ~100M in revenues. Just with the current revenues x5 we should be trading at a 500M market cap. If we consider the current pipeline, we should be trading at a 1B MC.".

  6. Current fair value: 1B market cap = $14 / share. Buyout target, min $3B = $42. Current price: $5.17 because it's manipulated by Wall Street crooks who are going to pay for their manipulation (FINRA is going after their ass).

  7. Unusual Options Activity Alerted on $7.5 PUT Expiring: 08-20-2021 worth 928K.... An analyst doing clients a favor I believe. Lowers PT so clients can load up cheap. Then change PT after ESMO or siendo p3. This is how WS plays the game.

  8. "A mystery buyer has been buying 11/19 $7.50 calls.". Also a lot of Jan 2023 $7.5 calls were bought. Probably by the same person who bought the 7.5 puts and made a killing when the stock was manipulated down. A manipulator bought the 7.5 puts at 35 cent and sold them at 2.9 in a matter of days making close to a million dollar with help from a couple of analysts. FINRA will be investigating it. Now they're loading up so they'll probably want to manipulate the shares up.

  9. I expect before the September oncology conference and surely before the SIENDO results anytime starting October 1, stock should move up as short cover and artificial supply turn to real demand.

  10. Pfizer bought out cancer drug company Trillium. "Trillium Therapeutics' stock nearly triples after buyout deal with Pfizer valued at $2.26 billion". The stock has been manipulated down. Pfizer has a senior manager on Karyopharm's board. An investor I respect highly who knows this sector well wrote: "Well PFE has front row seat since CSO is on our board. Good chance buy out before end of year? I’m mad at myself for not loading up more shares under $5"

  11. More cancer targets and drug combos on the way. Now welcoming $AZN with AZD-6738 and better understanding the roadmap for Antengene ATG-018 along with a few compounds licensed from Karyopharm - ATG-019, ATG-010, ATG-016, followed with anti-PD-1 antibodies ($BMY OPDIVO, $MRK KEYTRUDA) for ICB therapy.

  12. CEO: "XPO1 inhibition which can work across a number of solid and hemiotological inhibitions. Foundational to creating cancer cell death."

  13. "funds reallocated to KPTI will do their job in the next 2 q’s. I am betting 10+ @ ye"

  14. If you have any doubts about Karyopharm read this:

  15. European Society For Medical Oncology (ESMO) September. Expecting news from Karyopharm.

  16. You’re missing many data read outs at esmo (sept) and ash (dec). And q3 & q4 earnings can surprise as well. Not to forget the many approvals in Asia by antigene, the asian partner. Or the possibility of a BO, as kpti is ultra cheap right now. Other than that not many catalysts.

  17. "KPTI $15-18 BO , unique mechanism and deep value for combination with immune therapy!" -- "$27-$32 b/o pre ESMO. After ESMO: $60"

  18. Jim Cramer as a great contrarian indicator. Hear it from the evil beast's mouth who declares truth as the enemy: "But what’s important when you’re in that hedge fund mode is to not do a thing remotely truthful, because the truth is so against your view that it’s important to create a new truth to develop a fiction... You cannot do illegal tactics, but you do it anyways because no body understands it." So when he says SELL it's time to BUY. Friday the stock did exactly that. So Kramer is a useless evil clown who likes to breaks the law and mast it as "entertainment". The only use of his ugly face is to be a contrarian indicator. When his masters tell him to say SELL it means they're all BUYers and the want YOU to sell so they can BUY and they use their puppet to lie to you, deceive you, part you from your hard earned money so they can make money. Kramer is on record for having admitted this model of ugly business.

  19. Just listened to the Canaccord talk. I know the stock price and it doesn't seem like it will ever find a bottom, but there is a lot to be positive about. Paulson was solid; seemed to understand--and express effectively--the intricacies of the job in all aspects. Many trials. Over the next six months, we will have at least three data readouts, as well as other catalysts. I am encouraged. I recommend you take 25 minutes out of your time and give it a listen. Btw, the Eltanexor trial in refractory myelodysplastic syndrome will be exciting. Phase 1 results were encouraging in an indication with no effective treatment.

  20. I live buying in when others are angry. That’s how I know I am getting a good deal. :)


Some shareholders are losing their minds and ignorantly are being played in the hands of the manipulators who know some people can only take the pressure so much, so they attempt to break you down and steal your shares. Generally, only the strong prospers. And it takes a lot of strength to not get broken down psychologically. Some shareholders are losing it and are helping the manipulators by bashing the stock on social media in order to vent their frustration. Bad move. Eat your frustration, write it to yourself, but don't bash your own stock. Get smart. One crazy thing one wrote was about analysts. Most analysts are standing firm behind KPTI and are very optimistic. Here's an example from August coverage:

- Morgan Stanley: Overweight. Price Target $29.

- HC Wainwright: Buy. PT $26

- Baird: Outperform. PT: $17

I still think we can get a sudden buyout announcement anytime at a mind-blowingly high price. Both Bloomberg and Barclay have had KPTI on list of buyout targets.

18 AUG 2022 - Stock, Options, Manipulation, FINRA

I'll be filing an investigation request to FINRA to check the manipulation of KPTI including the blatant action of an analyst who obviously engaged in manipulation via his clout. Had a look at the strange trades today. That's also something FINRA will be asked to look into. If anyone has an idea on how to explain this please let me know.

Looking at the intraday chart which made me curious about options because sometimes manipulation is done in pairs. For example once we busted some reverse conversions on $ARNA. And FINRA took action and stopped it for good! Here's the detail:

Not saying it's the same but it's curious. Someone walked KPTI down from 4.80 to 4.60 and 2 things happened then. A 320,000 7.5 August put trade happened at 2.90. 7.5-2.9 = 4.60 and a 320,000 share stock trade happened at around the same price. They seem related. Anybody can explain it? Seems the option trade was a closing position (we'll know tomorrow).


An investor wrote a message to CEO Richard Paulson (see below). The first paragraph is his response after the CEO's presentation where the investor's point was addressed.

Looks like I was right!!! Richard confirmed during the call. That is great news. Next month before esmo also huge. I will implore Richard to make sure there is a press release letting the world know that Selinexor has efficacy against KRAS mutations.

In KPTI’s 2Q 2021 corporate presentation slides P115031 - KPTI 2Q21 Earnings Slides ( (page 24), KPTI discloses that two new clinical studies in CRC (XPORT-CRC-041) and NSCLC (XPORT-NSCLC-039) are “coming soon.” These clinical trials appear to be related to RAS mutated disease. In addition, footnote 7 says that these studies are supported by Phase 1 data from XPORT-STP-029. To date, I have not seen any data published by KPTI regarding CRC or NSCLC from this XPORT-STP-029 trial. I assume this is data that will be upcoming and presented at ESMO 2021. I also assume the data is positive—otherwise KPTI would not be commencing these new trials!

Given that KRAS is very hot right now, please consider saying something during the call about Selinexor’s potential in KRAS mutations in CRC and NSCLC given positive results in a recent trial and further that additional data will be presented at ESMO 2021---in about a month. Reminding the analysts that there is significant potential for Selinexor in KRAS can only help us.

[By the way, KRAS mutations are present in approximately 25% of tumors, making them one of the most common gene mutations linked to cancer. They are frequent drivers in lung, colorectal and pancreatic cancers. KRAS drives 32% of lung cancers, 40% of colorectal cancers, and 85% to 90% of pancreatic cancer cases.]


Another investor friend of mine who follows KPTI closely wrote along the same lines:

September ESMO release of solid tumor trial data looks promising. Listen specifically when asked about solid tumor strategy @ 22:30 - specifically regarding a 3rd line CRC study and NSCLC... in that space (KRAS mut) **finalizing plans on moving forward** (23:40) -

"At 23 minutes into the video - "We're really excited about data we've submitted to be presented at ESMO... in September... 3rd line CRC RAS-mut... and refractory NSLC... key areas we are moving forward with [incl. GBM, Melanoma]"


Another investor wrote: X is doing clients a favor I believe. Lowers PT so clients can load up cheap. Then change PT after ESMO or Siendo Phase 3. This is how WS plays the game. imho of course 😏

16-AUG-2021 -- Excellent Analysis


  • Morgan Stanley: Overweight $29 (overweight doesn't mean fat in this context, it means positive)

  • HC Wainwright: Buy rating. Price Target: $26

  • Baird: Outperform rating. Price Target: $17

  • Never mind the big short. It must have its head in the ass of the hedge fund short clients (see section below for explanation). Their analyst wrote the lousiest hit piece to apparently help short sellers cover. His logic stinks. He sounds like a total hypocrite (compared to his other recent reports when he wasn't in a "trash talk" mode for wicked reasons).

Morgan Stanley reiterated Buy rating with $29 Price Target.

Kramer is bashing to help the crooks cover their short position (what else is new)? It's a very bullish sign. Read about Cramer & his gang here.

Jim Cramer is a great contrarian indicator. Hear it from the evil beast's mouth who declares truth as the enemy: "But what’s important when you’re in that hedge fund mode is to not do a thing remotely truthful, because the truth is so against your view that it’s important to create a new truth to develop a fiction... You cannot do illegal tactics, but you do it anyways because no body understands it." So when he says SELL it's time to BUY. Friday the stock did exactly that. So Kramer is a useless evil clown who likes to breaks the law and mast it as "entertainment". The only use of his ugly face is to be a contrarian indicator. When his masters tell him to say SELL it means they're all BUYers and the want YOU to sell so they can BUY and they use their puppet to lie to you, deceive you, part you from your hard earned money so they can make money. Kramer is on record for having admitted this model of ugly business.

CEO SPEAKS: Karyopharm CEO Richard Paulson: "Everyone believes in the efficacy of selinexor."

13 August 2021 - KPTI is a Strong Buy

in my book. The price has lost 50% for no good reason at all except some analyst bashing it to help their short-seller client cover. That's the only reasonable explanation I can find. Nothing has changed about the story since the stock was about $11 a month or so ago. The drug works really good, it saves lives, new CEO, new hotshot sales management, multiple approvals, international presence, increasing sales, big solid tumor data should be out in a couple of months so I don't believe the stock will stay this low for too long. Company has reiterated three times recently that sales this and next quarter will be stronger.

An analyst recently gave it a target of $26. Do your own research. I'm very optimistic for good reasons. If solid tumor data is out on this first indication for which there's no other medicine (and it opens the door for other solid tumors), the price will go through the roof. All the analysts have said it'll be huge.


As an old investor friend used to say, put on your tin hats and bunker down. Those who followed his advice and held make a bundled (5 fold on their money when the stock that was being bombarded with the kind of FUD we see now about KPTI, was bought out at 8-times higher price.


  • Morgan Stanley: Overweight $29 (overweight doesn't mean fat in this context, it means positive)

  • HC Wainwright: Buy rating. Price Target: $26

  • Baird: Outperform rating. Price Target: $17

  • Never mind the Big Short. It must have its head in the ass of the hedge fund short clients (see section below for explanation). Eric Joseph wrote the lousiest hit piece to apparently help short sellers cover. His logic stinks. He sounds like a total hypocrite (compared to his other recent reports when he wasn't in a "trash talk" mode for wicked reasons). Like they did back in ARNA days (and turned positive after shorts covered). Comparing their May note to their August note, it's obvious that they're apparently trying to trash-talk the stock to apparently help their short-seller clients. They did that with another company I followed before then changed their tune once the shorts coverred. In KPTI May report they highlighted the SIENDO opportunity in the main body of the coverage and didn't say anything about cash/share. In their stupid hit-piece of August they didn't even mention SIENDO in the main body of the coverage!!

In June they called XPOVIO a drug with blockbuster potential. In August they knew far too well that the launch for 2nd line is new, but they still cluttered it to bash the product, and they shamefully even called it a product problem but cunningly put it in the form of the question but in the title they didn't put it in the form of a question. All the classic signs of a hit piece designed to disparage a company that the writer knows is a great company -- that's a high form of intellectual dishonesty on the part of the Big Short equity research which is supposed to be independent from other parts of the bank (SEC's Chinese Wall). But is it? I don't think so.

Shame on the Big Short analyst. Also he asked the most stupid question on the conference call to bash the company with irrelevant gossip. Richard Paulson did a great job of diffusing it. The next act was the dishonest low-life Jim Cramer, bashing the stock. It's not a coincidence. We're talking about the worst of Wall Street trying to manipulate people to sell their KPTI shares so some lowlife short seller can cover. Just in my opinion.

13 August 2021 -- Antengene will soon start marketing of Karyopharm's Selinexor in South Korea now that approval has been granted. Now Big News from China by Karyopharm partner Deqi

Remember: Selinexor is a selective nuclear export inhibitor (SINE) targeting the key nuclear export protein XPO1, originally designed and developed by the American biopharmaceutical company Karyopharm Therapeutics. In May 2018, Deqi Pharmaceuticals reached a cooperation with the company and has the right to develop and commercialize the drug in the Asia-Pacific region.

Remember: Multiple myeloma accounts for 13% of hematologic cancers, and yet the prevalence of incidence of the disease in China has remained something of a mystery. Now, a new study puts a number on the size of the problem. About 84000 Chinese have multiple myeloma. Same rate as in other Asian countries. “MM should be one of the cancers in the spotlight from both medical and socioeconomic perspectives... incidence of more elderly MM patients in the next decade".

About 84000 Chinese have multiple myeloma. Selinexor is the hot new player in this space in China, and Karyopharm should reap strong revenues.

Today: Here's a translation of a Chinese press release by Karyopharm's partner:

Strategic cooperation is reached, Deqi Pharmaceuticals and Shanghai Pharmaceutical Holdings are united to accelerate the commercialization layout in an all-round way

PR Newswire/ 2021.08.13 05:42

SHANGHAI and HONG KONG, Aug. 13, 2021 /PRNewswire/ -- On August 12, 2021, Deqi Pharmaceuticals and ShangPharma Holdings reached a strategic agreement on the world's first oral selective nuclear output inhibitor, Selinexor (FDA-approved proprietary English trade name: XPOVIO®, generic English name: selinexor), for import licensing, distribution, supply chain services and The company has reached strategic cooperation intentions and signed strategic agreements at various levels, including import licensing, distribution business, supply chain services and value-added innovation. The signing ceremony was attended by Mr. Jianming Mei, the founder, chairman and CEO of DEQ Pharmaceuticals; Mr. Bo Shan, the Chief Scientific Officer of DEQ Pharmaceuticals; Mr. Yiteng Liu, the Chief Operating Officer of DEQ Pharmaceuticals; Mr. Lixin Yu, the head of the Hematology and Oncology Division of DEQ Pharmaceuticals; Mr. Yongzhong Li, the Executive Director and Vice President of Shanghai Pharmaceuticals and the General Manager of Shanghai Pharmaceuticals; and Mr. Lu Lu Song, the Deputy General Manager of Shanghai Pharmaceuticals.

Deqi Pharmaceuticals and Shanghai Pharmaceutical Holdings signed a contract

Deqi Pharmaceutical signed a contract with Shanghai Pharmaceutical Holdings

In this strategic cooperation, Shanghai Pharmaceutical Holdings will act as the domestic import distributor of Celinisol for Deqi Pharmaceuticals and provide one-stop import distribution services for Deqi Pharmaceuticals by leveraging its advantages and mature experience in import customs clearance, channel distribution, tender linkage and market access. In addition, the two companies will leverage the quality and efficient supply chain service and the DTP pharmacy network under the cooperative channel of Shanghai Pharmaceutical Holdings to jointly explore the innovative areas of DTP pharmacies that directly serve patients, PAP pharmacies that support patient assistance programs, and innovative finance and commercial insurance.

Celinisol, the first and only oral selective nuclear output inhibitor (SINE) compound of its kind in the world, has been granted New Drug Marketing Application (NDA) priority review status by the National Pharmaceutical Administration (NMPA) of China on February 24, 2021 for the treatment of patients with refractory relapsed multiple myeloma (rrMM). In addition, several clinical trials of Selenisol in relapsed refractory large B-cell lymphoma, endometrial cancer, non-small cell lung cancer, myelofibrosis and peripheral T-cell and NK/T-cell lymphoma have been initiated in China, and most of the trials are in the post-clinical stage. DeQi Pharmaceuticals has maintained close communication and cooperation with regulatory authorities to facilitate the early launch of Celinisol and bring innovative therapies to patients in China as soon as possible. Shanghai Pharmaceutical Holdings is a nationwide modern pharmaceutical supply chain service enterprise with its core business in pharmaceutical distribution. Its scale of pharmaceutical distribution ranks among the top large pharmaceutical distribution enterprises in China and has established a terminal network covering more than 20,000 medical institutions nationwide. The strong alliance between Deqi Pharmaceuticals and Shanghai Pharmaceutical Holdings marks the speeding up of the commercialization of Deqi Pharmaceuticals.

Mr. Jianming Mei, Founder, Chairman and Chief Executive Officer of DEQ Pharmaceuticals

Mr. Jianming Mei, Founder, Chairman and Chief Executive Officer of Deqi Pharmaceuticals

"We are pleased to be working with ShangPharma Holdings as it offers a new treatment for patients with refractory relapsed myeloma multiforme. By leveraging the strength of ShangPharma's business network and channels, combined with DeQi's own leading R&D capabilities and academic expertise, we will be able to bring Celinisol products to patients in China as soon as possible. At the same time, we look forward to more collaborations in the future to leverage the strengths of each party to bring more first-in-class and best-in-class innovative drugs to patients in need," said Mei Jianming, Founder, Chairman and Chief Executive Officer of DEQ Pharmaceuticals.

Li Yongzhong, Executive Director, Vice President of Shanghai Pharmaceutical and General Manager of Shanghai Pharmaceutical Holdings

Li Yongzhong, Executive Director, Vice President of Shanghai Pharmaceutical and General Manager of Shanghai Pharmaceutical Holdings

"The collaboration between Shanghai Pharmaceutical Holdings and Deqi Pharmaceuticals is very meaningful, as the two companies will work together to help commercialize Celinisol in a number of areas and provide protection for patients with hematologic tumors. Shanghai Pharmaceutical Holdings will continue to provide a full range of services to Deqi under the philosophy of "Service is Pride"," said Li Yongzhong, Executive Director, Vice President of Shanghai Pharmaceutical Holdings and General Manager of Shanghai Pharmaceutical Holdings. We look forward to leveraging our respective resources to accelerate the development of innovative medicines in China for the benefit of more patients.

About Selenisol

Celinisol is the first and only oral XPO1 inhibitor approved by the U.S. FDA, and the first drug that can be used to treat both myeloma multiforme and diffuse large B-cell lymphoma. By inhibiting the nuclear export protein XPO1, it induces the nuclear storage and activation of tumor suppressor proteins and other growth-regulating proteins, and downregulates the levels of various oncogenic proteins in the cell plasma, inducing apoptosis in tumor cells, while leaving normal cells unaffected. Due to its unique mechanism of action, Celinisol can be used in combination with a number of other drugs to enhance its efficacy.

12 August - CEO at Canaccord

11 August - CEO Remark shows confidence about the extremely important SIENDO trial which will be huge for the stock if positive.

CEO said at Wedbush conference yesterday: "XPO1 inhibition which can work across a number of solid and hematological inhibitions. Foundational to creating cancer cell death."

This is yet another indication that the company and its partners are optimistic about SIENDO trial results. Recently a Karyopharm partner reported that they're counting on Selinexor working on solid tumors too and are already planning around that.

People who understand the science, the mechanism of action, and phase-2 data are confident about the outcome of SIENDO trial. These also include a few investors I personally know who have big money on the company and understand the science/sector well.

If SIENDO is positive, it will lead to lots of upgrades and much higher price targets, and faciliate buyout. Regarding impact on the short interest which will be forced to cover, as the author of the recent Reddit article put it: "This [SIENDO] is a stick of dynamite in a room full of matches."

10 August - Buyout Price Targets

Just got around to processing this email I got from a friend who follows KPTI closely and is very optimistic about the company:

Hi Reza,

Guessing $27-$33/share buyout if before solid tumor approval, 2x this with, and $100+ if they show efficacy with KRAS treatment combo (AMGN, MRTX have KRAS inhibitors). That work is only preclinical now and would not reach an approval for a few years in the best case-!/9325/presentation/1990

100K worldwide patient population of lung, colorectal and other KRAS G12C mutant solid tumors.

MRTX main investigational therapy/drug is a KRAS inhibitor and they are worth $8B.

AMGN is closing in on approval, no other drug is approved yet.

Interestingly, VSTM has a KRAS inhibitor in the clinic. MK is on the board. They got a new CEO in 2019 who sold off their approved compound to focus on their pipeline of more valuable assets.

Also interesting, see ATG-016 (eltanexor) details here, related to KRAS treatment. I am guessing they might use a combo with ATG-012.

9 August - KPTI Commentary & Upcoming Events

As always, I don't provide investment advice - but just share my research and humble opinions.

- Two conference presentations this week. A live webcast of the panel and fireside chat can be accessed here

  • Wedbush PacGrow Healthcare Virtual Conference - Date: Tuesday, August 10, 2021 - Time: 8:35 AM Eastern Time

  • Canaccord Genuity 41st Annual Growth Conference - Date: Thursday, August 12, 2021 - Time: 3:30 PM Eastern Time

- A friend was saying he had a panic attack when KPTI dropped like a rock. I managed to stay calm but it was painful to see the drop which was totally unjustified. Biotechs drop like this when there's bad data. KPTI has had good data all along, a very efficacious drug with multiple approvals -- and big results for solid-tumor (SIENDO) trial is coming out in Q4. And the sales management has been very upbeat about prospects.

Anyway, reminded me of my past biotech investing and how painful it was at times. And investor friends I knew and how they did. The ones who were convinced of the investment and held through thick and thin made a killing. In one investment I didn't have the nerves to hold longer -- but some of my friends did -- and they made a killing. One used to call it bunkering down when shorts attacked and their analysts were bashing the stock (figures like Maged Shenouda of UBS and Jonathan "Asscough" of Bream Murray... Now with KPTI we have our own version of puppets of short sellers). He ended up selling his shares for 5 times the price it was when shorts were all over it.

An "equity research" department of a major broker was engaged in trash talking ARNA when ARNA had a huge short interest. To help the shorts? We never know but apparently so. Now the same game is played against KPTI. At least they didn't issue a sell rating and they put the important upcoming positives in tiny footnotes to downplay the real potential of the stock. But x is not the only broker in town. Another broker issued a $26 price target.

So for me this is time to bunker down and let this storm pass. KPTI has two upcoming conferences this week and after this crazy short attack the stock should recover and get back to pre-attack levels in due time. The nice things about a big short interest is at some point when they feel the stock has bottomed, their artificial supply reduces while real demand increases -- a double whammy that can fuel a turnaround. I don't think KPTI needs news per se for a turnaround because the current value is so ridiculously low. It should return to some equilibrium which in reality should be in teens but at least $8-$11 range.

But for people including myself these drops can be depressing and very difficult. It takes introspection, revisiting one's investment thesis, and getting inner strength, lack of fear, and faith, to stand strong and not let the powers who want me to sell make me sell. I'm talking first person because I want to make sure I'm not sounding like I'm giving investment advice which I never do. Shorts want us to sell. Prospective acquirers of the company want us to sell. But I'm holding on to as many shares as as I can because I believe in this company's science and future, in the new CEO and his ability to turn the company around, in our superstar new sales VP, in the drug itself which is helping people live longer and enjoy life with their loved ones, etc.

I do believe Karyopharm's stock price will be much higher, and that it could be bought out sooner than later. If the upcoming solid tumor data is positive, it could get taken out at Barclay's $60 buyout target. SIENDO is so significant that the stock may start running up in anticipation because if the data is positive and the company is one of the heaviest shorted stocks on Nasdaq, it could be an overnight multi-bagger.

Best wishes


8 August - My take on the conference call

I was very impressed with the conference call. The new CEO is assembling a hotshot team. New VP of sales is a superstar. One analyst who's obviously prostituting for the hedge fund shorts was trying to pull gotchas during the call but he was diffused. His head is in the sand and ignoring the fact that we're early in the launch in second line, and that the company's doing well and the near- mid- term potential warrants much higher valuation -- I'd say at least double current value. So good job HC for issuing a $26 price target.

The rogue analyst went on to write a bogus note. If you put his questions on the call, which the CEO masterfully handled, and his "research" note, it's clear he's being played like a good prostitute by the hedge fund short's playbook, reciting their lines which are mundane, old, and irrelevant.

Ok shorts managed to get the price this low. Now what? They still have a problem that they need to cover. They haven't forgotten that SIENDO data is around the corner which could make the company's value triple overnight -- sales are increasing (management really stood behind that projection), and lots of other goodies in the works, not to mention a buyout because the Selinxor works really well. Today I heard an oncologist say it has a "elegant mechanism of action" which is much in demand when you're trying to save a person's life!

Looking forward the KPTI going a lot higher in the coming weeks. Just iun my opinion of course.

8 August 2021 - Someone posted this very inspirational message

Reminds me of Sava last year. I bought 3k shares at $9 and it immediately went down to $7. Sold at $43 two months later for $100k gain. Its now at $90!

8 August 2021 -- HC Wainwright & Co. reiterated coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $26.00

$26 is a good price.

8 August 2021 -- Highlights From The Very Upbeat Karyopharm (KPTI) August 5, 2021 Earnings Call

· Karyopharm was found on the innovative science of selective inhibition of nuclear export as a mechanism to treat a broad range of cancers with significant unmet need. The foundation in oncology was established with the regulatory approvals and commercial launches of XPOVIO in three immunological oncology indications.

· Specifically, in multiple myeloma, I believe we have a great opportunity to continue expanding our breadth and depth of XPOVIO through our execution in the approved indications and advancing our late-stage combination studies, which Jatin will cover later in the call.

· This includes our Phase 3 SIENDO study evaluating XPOVIO and endometrial cancer, where there are no approved treatments for maintenance therapy following chemotherapy in any line of treatment. Top line results for this study are expected by the end of this year. And if positive, further reinforces the therapeutic potential of XPOVIO in solid tumor indications.

· we're well capitalized to fund our operations with a cash runway into the middle of 2023.

· Please now turn to slide 7. Total XPOVIO net product sales for the quarter were 20.2 million, an 8% increase compared to the second quarter of 2020. Year-to-date sales for the first half 2021 were up 21% compared to the first half of 2020. Several key indicators continue to show progress, including growth in prescription demand quarter-over-quarter, and over 7,600 prescriptions filled as of the end of the second quarter.

· XPOVIO unit demand was at 28% compared to the second quarter of 2020, up year-to-date 33% compared to the first half of 2020 and up 4% from the first quarter of 2021. According to our market research data, we see a rising confidence in treating physicians overall perception of the XPOVIO product profiles across lines, and an evolution from penta-refractory to early aligns with strong growth in the third line.

· We're also reaching more customers and seeing the number of prescribing accounts continue to sequentially increase quarter-over-quarter with 11% growth compared to the first quarter of this year.

· We're still in the -- early in the rollout of XPOVIO in the second line plus setting and expect the average duration of treatment to increase over time as more and more patients are treated in early align with a once weekly XPOVIO dose and as part of a combination triplet regimen. Importantly, approximately 97% of us live have confirmed access to XPOVIO if prescribed.

· These tablet options may also increase patient compliance by simplifying their treatment regimen, and reducing the pill burden experienced by some patients.

· Please now turn to slide 8. Overall, the quarter showed promising growth across several indicators and we continue to believe there is more work to be done to further increase our position in the market and better expand the reach of XPOVIO. We have recently implemented key initiatives designed to achieve just that. We have de layered and strengthened our commercial team with key additions in marketing and the creation of a launch excellence capability to enhance our execution.

· there is a wide space in the middle section of the treatment journey between the second and the fourth line we're using a different mechanistic approach, also known as a class switch could be vital for the success of the patients’ outcomes. XPOVIO is the first new class of multiple myeloma treatment approved in five years, with the ability to combine with different regimens as recognized per the NCCN guidelines.

· With the foundation we are laying now, and with a rapidly advancing myeloma pipeline, we believe we will continue to drive a steady growth in the near, medium and long term.

· We're making progress on bringing XPOVIO to patients in need across the globe, with the recent approvals in the United Kingdom and South Korea that are further outlined in slide 10.

· Our priority Phase 3 study is the SIENDO study, evaluating XPOVIO in patients with endometrial cancer in the maintenance setting. SIENDO is enrolling approximately 248 patients, randomized 2:1, to receive either 80 milligrams XPOVIO once weekly or placebo.

· Eligible patients included those with stage IV or recurrent disease who have completed a course of taxane-platinum combination chemotherapy and achieved either a partial or complete response. The primary endpoint of the trial is an improvement in progression free survival, or PFS, and is defined as time from randomization until death or disease progression.

· In November of 2020, we announced the trial had passed its planned interim futility analysis. And so the study continues as planned and we expect the top line data by the end of this year.

· We remain highly encouraged by the study and the opportunity for exposure in this disease area as a maintenance therapy which is outlined on slide 12. Endometrial cancer is the most common gynecologic cancer in the US with over 65,000 new cases.

· Now while most women are diagnosed with early stage disease and have a good prognosis after surgery alone, approximately 14,000 patients each year in the frontline will have advanced or metastatic disease and are treated with chemotherapy. When their disease progresses, these patients are typically treated with additional chemotherapy, immunotherapy and/or targeted agents.

· However, currently there are no approved drugs in the maintenance setting for patients who had a response to chemotherapy in any setting. This is the setting in which we're studying XPOVIO in the SIENDO study. A similar approach was taken with PARP inhibitors for patients with ovarian cancers. And they're used in a maintenance setting and that disease is now the standard of care and widely adopted.

· To put our potential opportunity in endometrial cancer in perspective, assuming about two-thirds of frontline patients respond to chemotherapy, approximately 4,000 patients could be treated each year in the maintenance setting.

· We look forward to presenting these results later this year, which has the potential to benefit additional patients and has a significant opportunity to expand confidence in XPOVIO’s ability to work in both solid and hematologic tumors.

· We plan to initiate our Phase 3 study of XVd in multiple myeloma later this year, an oral combination that could allow us to further build in the multiple myeloma landscape. From our solid tumor programs, we expect top line data from the Phase 3 SIENDO study in endometrial cancer later this year. A market opportunity where there are no approved drugs in the maintenance setting, following chemotherapy in any line of treatment.

· We also plan to initiate multiple late stage clinical studies in Myelodysplastic syndrome Myelofibrosis and colorectal cancer. We expect to present combination data from both our hematologic malignancies, and solid tumor programs at medical meetings in the coming months, including ESMO in September. Lastly, we plan to hold investor day during the fourth quarter to review our strategic imperatives and pipeline priorities to support our evolution as a company.

· I like to underscore the demand growth that we've seen in the first six months of our launch in the second line, again, 28%, year-over-year for the quarter and 33% for the first half of this year versus last year and feel very good about this growth. Regarding some of the drivers that you mentioned around new patient starts and prescriber base, we're seeing very positive growth on new patients starts, as well as on expanding our user customer base as we're adding new accounts quarter-over-quarter. Furthermore, we're also seeing a gain in confidence based on our intent to prescribe data of physicians and their overall perception of the product.

· the rationale for exploring Eltanexor and MDS is really based on two things. One is strong pre-clinical rationale. We have early data from selinexor and MDS and now additional data with Eltanexor and MDS as well. And keep in mind two things. One, there's no approved indication – no approved therapies in the relapsed MDS space. And other therapies, including [indiscernible], which are effective drugs, have a response rate of less than 10% in relapsed MDS, especially primary refractory MDS.

· So in that setting that we're looking at the overall response rate of 53% with Eltanexor as a single agent, the overall survival greater than nine months or an expected survival of three to four months. So it's in that setting that we see a strong rationale to develop Eltanexor in the single agent in refractory MDS as well as looking at combinations in the future and earlier lines of therapy. Similar thoughts…

· That's actually the same thought in Myelofibrosis. There's really outside of JAK inhibitors limited therapeutic options for patients in the relapsed Myelofibrosis space. There's a now new JAK inhibitor in that space, but really the same class of drugs. And so you'll see data coming out of ASH again, the strong preclinical rationale, and you'll see data coming out of ASH, where we see in an IST single agent activity with selinexor, given once weekly at a low dose in myelofibrosis, and is based on that we're moving forward with the studies that were planned.

· And we're also exploring a combination with [indiscernible] in the newly diagnosed setting. Again, keeping in mind that there's limited therapeutic options for patients with Myelofibrosis and only one class of drugs right now that are approved and Myelofibrosis JAK inhibitors we're seeing some single agent activity that's promising.

· Going back to the demand growth that we saw in the first half of the year is 33%, in the first half of this year, versus the first half of last year. So very good demand growth here.

· Again, we're still early in the rollout of the second line plus launch, and it takes time for the real world data to mature.

· We are seeing, as we said, really good progress and moving up into earlier lines of treatment.

· the perception on both the efficacy and tolerability profile of the product is improving.

· I feel very good about the momentum that we've seen in the first half of the year. I am also very excited by the team that we have in place, which is excited, passionate, and highly patient-focused.

· And I'm confident about the growth that will continue not just through the end of this year, but that will sustain in the medium and long-term as well.

· It’s still very early in our second-line launch. Going back to Sohanya’s point, I think our 33% demand growth year-to-date versus the same period last year shows very strong demand growth. And we're moving up into earlier lines and feel very confident on our continued progress and into earlier line.

· It's important to really highlights where we're going with XPOVIO and the schedule on dose, we really transition from high dose twice weekly to once weekly low dose. And that's what we're doing with the SIENDO study where we're dosing patients with 80 milligrams once weekly in the maintenance setting. And so we find that doses schedule, it's well tolerated, and many of our oncology line, oncologists are comfortable with XPOVIO management of side effects, and support of care there.

· As we move up into the earlier Alliance, we will see that progress, and we're seeing that, so we expect to start seeing that come through into the second half of the year, and it continues to move forward. Again, earlier lines with longer duration of therapy.

· In the maintenance setting, there are no approved therapies. So to have the ability to benefit patients in that setting was a positive study, I think you would see a very rapid uptake, just as we've seen in ovarian cancer with the PARP’s.

· And we had our first interim analysis in November of 2020 as we mentioned. We passed and continue the trial as designed and expect top line results by the end of this year. If we have a positive study, with a hazard ratio of 0.6 or less, that will be both statistically as well as clinically significant for patients. Mind you, that's in the setting where there is no other approved maintenance therapies in endometrial cancer and a place that people are looking for maintenance. And the GYN oncologists are comfortable using maintenance therapy, as Richard alluded to so.

· There is this unmet need, this gap, this white space in between the second line and fourth line, where there is a need for a class switch or a new class of therapy, where it can have an impact on patients' outcomes. And this is where we are positioning XPOVIO with its efficacy and strong tolerability profiles.

7 August 2021 -- "Don't listen to the analysts, listen to oncologists".

"Very Elegant Mechanism of Action"

Suzanne Lentzsch, MD, PhD: Selinexor is a very interesting drug that was developed and designed based on extensive laboratory research. The mechanism is very interesting, because it inhibits a protein that shuttles other proteins from the nucleus into the cytosol. By doing this, it basically stops cell cycle. Without having any proteins going from the nucleus to the cell cycle, the cell cannot grow or produce more proteins. It’s a very elegant mechanism of action. Interestingly, high-risk cytogenetic multiple myeloma seems to be especially sensitive to selinexor; for instance, patients with 17p deletion. We saw on the BOSTON trial that patients benefited very well and to a higher extent from the selinexor-bortezomib combination in comparison with other patients who had normal-risk cytogenetics. I found that mechanism very interesting.

Hot pipeline

5 August 2021 -- I'm holding on till at least Siendo data. Buyout written all over this anyway. That's why Richard came on board, I believe. He saw it as a low hanging fruit for big pharma. Get the sales going and boom, it'll get bought and he makes his 100 million.

Wrote that note to a friend.

5 August 2021 -- China

An investor wrote: Need to put things in perspective. Population china vs US is 4.35. China has 3X more people than the US. KPTI got the best sales team in China. XPOVIO is an oral pill which is a lot easier to push than other therapies in China due to the lacking of healthcare facilities to meet the demand. Plus a lot of the cancer therapies in the US have not gotten over there. So XPOVIO will go great in China. The APAC sales will be greater than US+Europe combined.

5 August - No Fundamental Reason For The Price Drop Except Wall Street Games

KPTI is way over-sold in my opinion. There's absolutely no reason for this huge drop. I'm holding on to my shares. I didn't see anything in the press release or conf call that made me want to sell. The call was very upbeat. The new sales chief is a super star. They're on top of it. SIENDO trial data in a couple of months or so should put them in double-digits if not before. Nothing has changed in my investment thesis. So I'll hold and ride this out.

4 August - Very Optimistic About KPTI

Nonsense stock price drop. KPTI's great story hasn't changed a bit. The drug works really good. It has multiple approvals and getting more approvals globally. Solid tumor data could be out as early as 2 months. Analysts are very optimistic. Stock very undervalued. The last inept CEO who ran the company to the ground by mismanagement has been replaced with a CEO who has a solid track record of success, who left a great job to lead KPTI. Current earnings don't matter to me that much. I believe the company will be bought out sooner than later. So nothing in my investment thesis in Karyopharm has changed or has declined -- if anything, I'm more than ever confident about the company's future.

3 August - new conference presentations

2021 Wedbush PacGrow Healthcare Virtual Conference

Date: Tuesday, August 10, 2021

Time: 8:35 AM Eastern Time

Canaccord Genuity 41st Annual Growth Conference

Date: Thursday, August 12, 2021

Time: 3:30 PM Eastern Time

A live webcast of the panel and fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website,

Most patients with MM eventually suffer from relapse or become refractory diseases. For patients who have failed in one therapy, diffuse large B-cell lymphoma (DLBCL) has poor prognosis and the chance of cure or long-term disease-free survival declined every time getting worse after treatment. At present, there is no cure for rrMM and rrDLBCL and it is in dire need for safer and more effective therapies.

In October 2020, selinexor was granted an Orphan Drug Designation (ODD) in South Korea, where the term "Orphan Drug" is defined by the MFDS as therapies used to treat diseases affecting 20,000 or fewer patients and therapies used to treat diseases for which no appropriate therapy has been developed, or therapies that have demonstrated significant improvement in safety and/or efficacy compared to existing treatments.

A new mechanism of action with a broad therapeutic window Selinexor's novel mechanism of action (MoA) which is based on the selective inhibition of the nuclear export protein XPO1, is different from that of all currently approved therapies. The drug can be combined with various therapies to deliver improved treatment outcomes in these diseases. To date, five selinexor-based regimens have been added to the National Comprehensive Cancer Network (NCCN®) Guidelines.

Minyoung Kim, General Manager of Antengene [Karyopharm’s partner], commented: "We are very encouraged by the MFDS' approval of selinexor. I am confident that this oral selective inhibitor of nuclear export protein, with its practice-changing therapeutic utility, will improve the quality of life of patients with rrMM and rrDLBCL in South Korea, and bring renewed hope to this patient population."


  • I think the one thing that stood out to me was a subset analysis in the BOSTON trial [NCT03110562] for the elderly patients.1 That is something I didn’t know and would be interesting to put into a second- or earlier-line therapy for our triple-refractory patients up front. FORSBERG: Of the subgroup analyses, I think that was the one that surprised me the most in terms of the consequences— we think that they did get that much benefit.

  • Patients on selinexor, bortezomib, and dexamethasone had excellent responses with disease. Outstanding response over remission....[There was a] patient who had triple-refractory multiple myeloma and had almost tried everything else already.

  • "Just published: "Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single‑agent selinexor in the SADAL study". From the abstract: "In a patient population in which survival is expected to be < 6 months, treatment with single-agent oral selinexor was associated with a median survival of 9 months".

  • A new publication: "Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts". Important finding: Monotherapy with Selinexor reduced tumor growth in all KRASmut PDXs, which included 4 different codon mutations, and was more effective than the clinical MEK1/2 inhibitor, Trametinib.

  • From a scientist friend regarding Karyopharm: Yes, this company seems very promising.

30 July 2021 - Profiles of KPTI's new top talents

  • Ms. Cheng brings 17 years of biopharmaceutical commercialization and research experience to Karyopharm, predominately in the oncology space. Prior to joining Karyopharm, Ms. Cheng served as Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals and prior to this role, spent over 10 years within the commercial organization at Amgen. While at Amgen, Ms. Cheng held a variety of sales and marketing leadership roles supporting the commercialization of key oncology brands, including Kyprolis® for multiple myeloma and Blincyto® for acute lymphoblastic lymphoma, and served as Amgen's Executive Director, Head of Marketing & Sales for their multiple myeloma business. Ms. Cheng holds an MBA from the MIT Sloan School of Management and a BSc and MA from the University of Cambridge, UK.

  • Dr. Darouian joined Karyopharm in January 2021 and is responsible for all marketing efforts for XPOVIO. Prior to joining Karyopharm, he spent more than 17 years in a variety of commercial leadership roles, predominately in the oncology space, including at Novartis where Dr. Darouian served as the Executive Director and Global Brand Lead for Targeted Lung Cancer Therapies and also led commercial strategy for their Solid Tumor and Immuno-Oncology business. Prior to Novartis, Dr. Darouian helped lead worldwide commercialization of Opdivo® for the treatment of head and neck cancer at Bristol Myers Squibb. Finally, while at Sanofi, Dr. Darouian held numerous marketing leadership roles over an eight year period supporting key oncology brands, including Jevtana® and Eloxatin®. Dr. Darouian holds a PharmD from the Albany College of Pharmacy and a BS from the University of Massachusetts, Amherst.

Excellent article. Here are some excerpts:

by "Dr. Due Diligence (DD)"

What if I told you there was a company with ~$290 Million dollars cash, a cancer drug with four approved indications, listed as a category 1 treatment option of choice by NCCN guidelines (important), is undergoing rapid expansion into other disease states, and I like the stock? How much would this company be worth on a market cap level if they are bringing in $23 Million dollars per quarter with in my opinion bad sales?

I was asked by u/ossbournemc about $KPTI and it was the top voted comment. This is a stock I have watched for a long time, and previously played the ADCOM recommended against approval (this is panel that evaluates before the FDA -ODAC specifically for Oncology Drugs) when they were comparing 2nd line efficacy of dexamethasone vs 5th line selinexor (two different beasts and shows a level of misunderstanding that is actually frightening). The stock went from $4 to $25 and I really enjoyed that. These are the types of opportunities I live for.

Coming in at the 22nd most shorted stock in the world is Karyopharm ($KPTI) with 23.04% shorted.

Would this company be worth $672MM? I don’t think so either, which is why I opened a small position.

Karyopharm ($KPTI) is a commercial stage biotech with indications for Multiple Myeloma (2nd Line+) and Diffuse Large B-Cell Lymphoma, and clinical studies currently ongoing for solid tumor indications.

Quick Ape Translation:

Shorted stocks are a huge opportunity to buy at a discount, but some stocks are shorted for good reasons and will never go up. Karyopharm ($KPTI) has huge upside potential with new leadership and increased indications for their drug that increased their addressable patient population (customers) by 632% (39200 now vs 6200 before). There is topline data coming in the next few months for endometrial cancer. This is a stick of dynamite in a room full of matches.

Disease Treatment Background:

Multiple Myeloma is a terrible disease with no cure that affects 35,000 Americans every year and more globally. Patients fall into two categories for the most part: those that can get stem cell transplant and those that can’t. MM typically affects those that are older, and if you are older then you are more likely to need chemotherapy rather than a stem cell transplant. There is no cure, essentially patients are given combinations, it goes into recession, then comes back, and given more treatment.

There is no cure for Multiple Myeloma (MM). Multiple Myeloma is treated until you pass away or go on Hospice, this means it goes Newly Diagnosed Multiple Myeloma→ Relapsed or Refractory Multiple Myeloma (lines 2, 3, 4, 5… etc). There are many treatment options available for MM, and they’re often given in combination (2 to 3 drugs at the same time) to try and make the disease undetectable, so there are longer periods before the disease comes back. This means that there can be multiple winners in this space. There are a lot of competitors in this space however Selinexor (XPOVIO) is unique in it’s Mechanism of Action compared to the competition which generally works the same way (proteasome inhibitor, immunomodulatory agents). This means that while other drugs can be substituted in regimens, there is no readily available substitute for selinexor.

What’s new:

Michael Kauffman was finally fired… ahem.. “promoted to senior advisor” and CEO title removed and his wife Sharon Shacham had her President Title removed. While they both have a scientific background and were able to do great things at their previous MM biotech in scientific roles (Onyx with Kyprolis), it was clear that they were not up to the task of building a commercial organization with their sales at several multiples below what they should be. There was every excuse in the book and the board had been planning this move for some time, as Richard Paulson (the new CEO/President) was brought onto the board last year and the plan was to cut them out probably before that. My question is why did it take the board so long? Michael and Sharon were given generous yellow metallic parachutes, titles, and still own 5% of the company each, so getting out of the way was probably the best thing to do.

Richard Paulson seems to be betting on the company and he also left IPSEN after only 3 years (sorry Ipsen Bros). His salary is essentially $1MM ($670K salary + 50% bonus which is almost always given), but he is getting 559,800 KPTI shares and 373,200 Restricted Stock Units. This may not seem like a lot, but if he is able to build the sales (which are already growing) and get licensing for the 2nd and 3rd largest markets for relapsed and refractory MM (2nd Line) then this company could take off. For example at a 10 Billion Dollar Market Cap (share price ~$133) his take home could be $74.4MM from the shares and (ignoring time) $49.6MM from the RSUs for a total of $124MM. Not bad for what could be a 18-24 month turnaround. If the sales increase significantly it will be a prime biotech buyout target.

It’s not in a bad spot to do that as after the company received additional indications (including category 1 NCCN recommendations shortly after) in December 2020 so they hired many new sales employees (onboard training in Pharma/Biotech can be about 3 months so this has not yet affected reported sales).

There’s 3 types of drugs:

Drugs that sell themselves (rare, think Viagra)

Drugs that need education on, and doctors are hesitant about (this is selinexor)

Drugs nobody wants. Right now the market has it at a 3, but it’s really a 2 and can help lots of patients. It has manageable side effects for a cancer drug and has great results.

It also has lots of high reward studies that the teams are being built out on currently. With only sales coming in from their old indication (penta-refractory - 5th Line MM), there being two other indications with NCCN indications that have larger patient populations available (2nd Line MM, DLBCL), and with the first registrational trial in a solid tumor coming out, this is the biggest turnaround opportunity in biotech. This stock priced so low, is in my opinion a can’t miss, and I even liquidated other investments to take advantage when the stock dropped to $8. This is a good buy even at $14. It may take time to truly turn this into a commercial organization, but honestly, it may not. Second Quarter Earnings are August 3rd 2021. This is the first quarter results that show the added sales force and the effect of leadership even if only for 2 months. It could surprise some people or it may take more time to build up sales. The sales force was pretty weak in 2020 and even the beginning of 2021 (1 in 4 visits were in person, so a majority were Digital i.e. Zoom). The anemic leadership is gone, the sales force is expanded and likely meeting doctors in person, and their last reported month of sales (March 2021) was already their highest month of sales ever.


There is a high probability based on quarterly earnings calls, top line data coming soon from SIENDO (endometrial cancer trial) will be positive. There is already a plan for two additional solid tumor trials this year which is a great sign. You don’t plan additional studies if the first study is performing terribly.

Licensing opportunities in Japan and EU.

Earlier line MM which has approval and a patient population is much higher, and currently the market is not penetrated, with penta-refractory MM driving past sales.

Heavily shorted stock (~23% of available shares, over 15MM) on an institutionally owned stock (78%). A catalyst could easily cause a short squeeze with 2+ weeks of days to cover.

Stock is priced like a clinical stage biotech when it is a commercial stage biotech (NCCN recommendations, FDA approvals, and favorable EU approval on STORM data, with BOSTON approval expected soon).

Multiple Myeloma biotech buyouts from Big Pharma are typically priced high, with additional study combinations coming in 2nd Line MM, including all oral study, there could be a buyout. For example Onyx Pharmaceuticals with Kyprolis was bought for $10 Billion Dollars in 2013. That would place KPTI stock price around $133/share.

CRADA with NCI (contract to allow government funded oncology studies) in July 2020, means this year or next some trials may emerge, including for additional indications.

Richard Paulson (new CEO/President who knows what he is doing) came in on May 3rd, and John “left to pursue other opportunities” on June 8th. Don’t feel too bad for John, he received 23,995 shares for a year’s worth of work for… this.

Read here as to why decisive action is the mark of a great leader. Richard Paulson not only has the connections for a potential buyout, but also has the experience running a commercial organization (something lacking before). He has already signed a royalty deal for $100MM cash (60MM upfront) to increase runway and have more flexibility. Judging by his compensation he took a much lower salary and bonus in order to maximize stock grants and options. He is betting big on the company, and if he can increase sales he can have a buyout/huge payday ($124MM+).

They hired a Super Badass Sohanya Cheng, MA, MBA for Senior Vice President of Sales and Commercial Operations. She left her position after only 6 months for this opportunity at Karyopharm, and negotiated one of the best deals I’ve ever seen under an inducement (125,000 shares with almost immediate grant date). Sohanya is betting big on the company. She and Richard (CEO/President) worked together at Amgen. He is bringing in his ‘A Players.’ This was only two months ago, and it can take time to see changes at a company, but it’s heading in the right direction and I look forward to the next several quarterly earnings calls.

When changes like this happen to an organization, it energizes it. Accountability is finally present at Karyopharm and when changes like this happen then results happen.

Prognosis: I like the stock.

26 July 2021 - Karyopharm's Covid-19 Treatment

Jul. 26, 2021

  • Results from a preclinical study jointly conducted by Antengene, Karyopharm Therapeutics (NASDAQ:KPTI) and University of Georgia College of Veterinary Medicine has been published in scientific journal, Antiviral Research, evaluating selinexor for prevention and treatment of SARS-CoV-2 infections.

  • Results showed that the nuclear export protein exportin-1 (XPO1) plays a direct role in SARS-CoV-2 infections and the pathogenesis of COVID-19; and the selective oral inhibitor of XPO1, selinexor, has potent anti-SARS-CoV-2 activity both in vitro and in vivo.

  • SARS-CoV-2-infected Vero E6 cells were incubated with varying concentrations of selinexor starting at 6 hours prior to the viral infection, at the time of viral infection, or at 0, 24, 36 and 48 hours post infection.

  • Results from the test showed that selinexor has potent anti-SARS-CoV-2 activity in vitro, with 50% inhibition of SARS-CoV-2 replication at 10nM and 90% inhibition at 100nM in the Vero E6 cells.

  • These tests also demonstrated that selinexor inhibited SARS-CoV-2 viral propagation in vitro even when added up to 48 hours after infection.

  • In the in vivo analysis in models of infected ferrets, animals were infected intranasally with SARS-CoV-2, then treated with either selinexor (5mg/kg) or placebo (vehicle only) for 3 days starting 4 hours after infection.

  • Three days after the infection, selinexor-treated animals had a mean viral RNA that was markedly lower than that of the placebo-treated animals.

  • Compared to the placebo-treated group, selinexor has also significantly reduced inflammation in the respiratory system.

  • Also, the study demonstrated that selinexor can significantly lower the ex vivo inflammatory cytokine release by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.


23 July 2021 - EMA Nexpovio Review Probably in August / View of an expert

An expert wrote to me:

Nexpovio wasn't mentioned because an opinion action was not taken. The good news is that a negative opinion was not taken! We wont know precisely what happened until the minutes come out, but I'm not at all worried. This will probably be back on the agenda next month or maybe even September. Not unusual at all--just means that we have to wait a little longer for approval. As you noted, given all the focus on vaccines, it's possible that they just ran out of time.

Good news.

19 July 2021 - EUROPEAN (EMA) REVIEW

GmbHRapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst Scope: “Group of variations including an extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and a quality variation for the addition of a new pack size to align with the dose modification guidance for the new indication. Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 6.5 of the SmPC are updated to reflect the new indication and the new pack size. Annex II is updated to reflect the completion of the Specific Obligation. The Labelling and Package Leaflet are amended accordingly. The RMP (v 1.1) is amended consequently.”Action: For adoption

19 July 2021 - RBC Capital Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)

In a report issued on July 8, Brian Abrahams from RBC Capital maintained a Buy rating on Karyopharm Therapeutics (KPTI Research Report), with a price target of $17.00. The company’s shares closed last Friday at $10.06.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Karyopharm Therapeutics with a $25.25 average price target.

17 July 2021 - Tremendous therapeutic benefit of XPO1 inhibitors

Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer

Our findings anticipate tremendous therapeutic benefit and support the further evaluation of XPO1 inhibitors, especially in combination with DNA damage checkpoint inhibitors, to elicit an enduring clinical response in patients with CRC harboring TP53 mutations.

15 July 2021 - Various

Some big investors saying they've been using this price weakness to add to their KPTI holding.

Also got this note from a biotech friend today:

"I wanted to point out that Mark Hoppus of the popular band Blink-182 has been diagnosed with diffuse large B-cell lymphoma. I thought that you would be interested in this in light of KPTI's drug selexinor having been approved for this indication. Not sure if his version is relapsed or refractory though.

On June 22, 2020, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy."

14 July 2021 - Antengene submits selinexor application in Taiwan in hematologic malignancies

14 July 2021 - Hedge Fund Short Puppets' Hit Piece

Meanwhile to help the shorts and/or prospective buyers, a hit piece is published that disparages the stock with garbage arguments like "insiders hate the stock". Fact is insiders love the stock. The chief medical officer recently bought a ton of stock in the open market. The sales the author is referring to are by the founders' planned sales, which has stopped, thank God. The ex-CEO told me 90% of his holding is in KPTI so his multiple financial advisors tell him that he should diversify -- nothing against the stock.

The guy who wrote the hit piece says his fund sold at 10, knowing this article would come out, and probably a few other shorts got the heads up too. Now the stock is a dollar lower and he claims to be long in the article, which just means he may have 1 share.

Hopefully good data and execution will wipe out these suckass hedge funds.

9 July 2021 - Buyout Price / Note From Investor / Expense Control

An investor with Dr. alias posted: "holding since $18. Could have dropped these bags multiple times and been fine with other plays but I held. I held because I think think this is going to rip or be bought out any day."

I agree. I wouldn't be surprised to get buyout news sooner than later. But if management is very confident about Siendo, it might wait after Siendo trial results. I think if Karyopharm gets a $30 offer now it will sell. Don't know. Barclays predicted $60 buyout price.

Why stop a Phase 1 trial? Probably because Richard Paulson rightly decided he can't throw money at everything under the sun like his predecessor who didn't seem to have a sense of what constitutes shareholder value, and you can't rely on shareholders indefinitely as ATM machines and burn through cash like wildfire. The new owner of Karyopharm will have a lot more money to pursue these things.\

8 July 2021 - Ian Karp Is Gone

Ian Karp, "Senior Vice President, Investor and Public Relations" is no longer with Karyopharm. No new employer is listed on his Linkedin profile. I wish him well.

New blood is good. Hopefully KPTI's IR will improve, or there won't be a need for it if the company will be bought out this year.

5 July 2021 - KPTI Partner Is Cooking

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

MF is a clonal hematologic neoplasm which can emerge either as primary MF, polycythemia vera (PV) or essential thrombocythemia (ET) [1] . Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment for MF. However, such treatment is difficult to carry out and has a low rate of success...

Selinexor is so far the first and only oral SINE compound approved by the FDA and is the first drug approved for the treatment of both MM and DLBCL. Selinexor is also being evaluated in several other mid-and later-phase clinical trials across multiple solid tumor indications, including liposarcoma and endometrial cancer. In November 2020 , at the Connective Tissue Oncology Society 2020 Annual Meeting (CTOS 2020), Antengene's partner, Karyopharm, presented positive results from the Phase III randomized, double blind, placebo controlled, cross-over SEAL trial evaluating single agent, oral selinexor versus matching placebo in patients with liposarcoma. Karyopharm also announced that the ongoing Phase III SIENDO trial of selinexor in patients with endometrial cancer passed the planned interim futility analysis and the Data and Safety Monitoring Board (DSMB) recommended the trial should proceed as planned without any modifications. Top-line SIENDO trial results are expected in the second half of 2021.

Antengene is currently conducting five late-stage clinical trials of selinexor for the treatment of MM, DLBCL, non-small cell lung cancer, and peripheral T and NK/T-cell lymphoma. Furthermore, Antengene has submitted New Drug Applications (NDAs) for selinexor in multiple Asia-Pacific markets including China , Australia , South Korea , and Singapore , and was granted the Priority Review status by China's NMPA and an Orphan Drug Designation by the Ministry of Food and Drug Safety of South Korea (MFDS).

Happy 4th of July - Lots of KPTI Updates

§ A KPTI-investor friend wrote: "Expecting NCCN to list selinexor as a preferred regimen for DLBCL 2nd line and subsequent therapies. Karyopharm submitted a formal request with supporting documents June 23 to the NCCN B-Cell Lymphomas Panel."

§ Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.

§ Dr Vij: “Selinexor is certainly an agent that has shown activity in triple-class refractory disease. It’s an agent with a unique mechanism of action and will be increasingly used in the months and years to come”

§ New NSCC Rule Change Poised to End the Short Squeeze Saga

§ Canaccord Genuity Thinks Karyopharm Therapeutics’ Stock is Going to Recover

§ Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export

§ Antengene Provides an Update on Its Latest Developments

§ Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021

§ Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

§ VIDEO; Selinexor combination highly active in heavily pretreated multiple myeloma

§ I am excited to announce that I have joined Karyopharm Therapeutics as Executive Director, Launch Excellence. I will be working closely with the Commercial and Medical Affairs team as we continue to serve patients with Multiple Myeloma and prepare for a best in class launch for Endometrial Cancer patients.

§ Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

§ Karyopharm taps longtime Pfizer, Amgen vet to steer the ship

§ Karyopharm Announces Key Changes to Its Commercial Leadership Team

§ Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo


Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

− Investment Expected to Extend Karyopharm's Cash Runway into the Middle of 2023 -

− Agreement Follows a Prior $75M Investment by Healthcare Royalty in Karyopharm in September 2019 -

26 Jun 2021 - New Logo

§ New trademark (logo):

§ Stock closed at the almost 3-month high (10.99).

19 Jun 2021 - Upcoming Discussion With CEO, etc.

One of our good friends will be having a call with the CEO soon. He's a seasoned biotech investor and knows KPTI's sector well. He noted:

§ "He [Richard Paulson] left a damn good job at Ipsen for KPTI". Indeed.

Also: "I was impressed with the eltanexor news."

He wrote: "You are my inspiration!" :-) Several "passive investors" have become "active investors" when they see it in action... It makes a difference to at least remind a public company's management about their priorities.

Another seasoned investor who works in oncology wrote:

§ "Great progress in KPTI land! Looks like the new CEO is making some good changes! May be time to get back in...". He had sold his stock due to disappointment with Michael Kauffman's leadership.

First investor wrote back in May (just catching up with my notes):

§ "This is huge because they (Morgan Stanley) have access to April script data. Also, if they are projecting annual 2021 revenue of $162M, after a lousy $21.7M first quarter, that’s some significant increases to come!"

18 Jun 2021 Antengene Provides an Update on Its Latest Developments

With the expected approvals for selinexor across multiple APAC markets towards the end of 2021, Antengene has continued to build up its experienced commercial team across China and the APAC region with plans to grow its commercial organization to up to 200 full time employees in functions including in-house marketing, field force, pricing and market access by the end of 2021.


Selinexor is a first-in-class, only-in-class orally available XPO1 inhibitor being developed for the treatment of hematologic malignancies and solid tumors.

§ Data from the MARCH trial of selinexor published at ASCO annual meeting in June 2021 include an objective response rate (ORR) of 26.7% in all analyzed patients with relapsed or refractory multiple myeloma (RRMM) and an ORR of 33.3% in patients with triple-class-exposed RRMM. These data are consistent with that observed in the STORM trial, from which, data had supported the accelerated approval of selinexor by the U.S. Food and Drug Administration (FDA). In addition, the data also showed an ORR of 44.4% in patients who had received prior CAR-T therapies.

§ Antengene has submitted a new drug application (NDA) for selinexor to the National Medical Products Administration (NMPA) in January 2021 with priority review granted to the NDA in February 2021.

§ Multiple combination regimens of selinexor have already included in the 2021 Chinese Society of Clinical Oncology (CSCO) Guidelines.

§ Antengene submitted NDAs for selinexor in Australia, Korea, Singapore and Hong Kong, and plans to submit an NDA for three indications in hematologic malignancies in Taiwan in Q3 2021.

§ Antengene is exploring additional indications of selinexor through two global Phase III registrational trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma (RRDLBCL, the XPORT-DLBCL-030 trial) and endometrial cancer (the SIENDO trial); two registrational trials for the treatment of RRDLBCL (the SEARCH trial) and RRMM (the BENCH trial) in China; and China-only trials including for the treatment of relapsed or refractory T-cell and NK/T-cell lymphoma (the TOUCH trial).

15, 19 Jun 2021 - OpEx Week

2724 call contracts (272400 share equivalent) at $10 strike are in play this Friday. The option writers have to work really hard to get the stock to close at $9.99 or below to make those options go worthless. If they don't succeed, people who bought those options want their shares at $10 so sellers of the calls have to come up with shares (buy in open market unless they're hedged which most probably aren't since serious investors who know the stock wouldn't sell $10 calls when this price range is clearly very manipulated and grossly undervalued). So we could see fireworks on Friday, and even challenge sellers of the 1790 $12.50 call options.


Nice end of a volatile week for Karyopharm. The stock closed up, which was a wonder given biotech indices as well as other indices were all in negative territory. Probaby due to the dynamics discussed above.

11 Jun 2021 - Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder

10 Jun 2021 - Stock is on a tear

It's still grossly undervalued. short float down 1.7% from 21.95% to 20.25%. Shorts have a lot more shares to cover. Fake supply turning to real demand = boost in the price. New CEO means business.


A friend of mine who owns millions in KPTI shares wrote to me yesterday:

§ "Well I'm not holding this stock thinking it's a under $50.00 investment :)"

§ (7 June 2021) In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics, with a price target of $49.00.

1. How could this one may ask, when the stock is 9.40? 9.40 to 49 is not unheard of in biotech. Even ten-baggers happen. I've seen them, and was invested in a stock that was in $2's, analysts had $12 target. Company was bought for $17 -- an 8-bagger.

2. KPTI's solid tumor data in Q4 this year can be a game changer. That's not even priced-in in most analyst models. And the company has a lot going beside that. And I believe just correcting past management mistakes, as Richard Paulson has started to do, could freak the shorts (22% of float) and fake supply will turn into real demand, a double positive effect for the share price.

9 June 2021 - Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

NEWTON, Mass., June 9, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that nine abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming European Hematology Association (EHA) 2021 Virtual Congress taking place June 9-17, 2021.

To view this release online and get more information about Investor Center | Karyopharm Therapeutics visit:


Karyopharm Announces Key Changes to Its Commercial Leadership Team

− Sohanya Cheng, Formerly of Amgen and Arrowhead Pharmaceuticals, Appointed as Head of Sales and Commercial Operations -

− Payman Darouian, Formerly of Novartis, Bristol Myers Squibb, and Sanofi, to Lead Marketing for XPOVIO® -

I hope this trend continues...

The new CEO is rocking out. He fired the CCO (John Demaree) and the SVP of Sales (Perry Monaco), and put some top-notch people in those roles instead. I hope the house cleaning will continue. The last CEO, though a medical genius, was a weak manager. Great quote about Steve Jobs explains the situation perfectly:

"My theory is that A players hire people even better than themselves. It’s clear, though, that B players hire C players so they can feel superior to them, and C players hire D players. If you start hiring B players, expect what Steve [Jobs] called ‘the bozo explosion’ to happen in your organization."- Guy Kawasaki, Chief Evangelist, Apple

8 June 2021 -- Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS


Jun 08, 2021, 20:00 ET

--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%--

--Patients with mCR had longer mOS than patients without mCR or with PD--

7 Jun 2021 - HCW Reiterates Buy with $49 Price Target

(7 June 2021) In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics, with a price target of $49.00.

4 Jun 2021 - Study Completes This Month

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

3 Jun 2021 - VALUATION

"JP Morgan called Constellation Pharma extremely well, and stuck with their high PT even when the stock was nudging below the $20 level.

Yesterday they noted that the CNST acquisition came "as somewhat of a surprise, as it is a little outside of sweet spot for biotech M&A, as reflected by recent deals (i.e., companies with at least de-risked phase 3 data in hand).

Lot's of similarities with KPTI here. JPM's PT is $21, and KPTI is generally more de-risked."


3 Jun 2021 - Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets

-- Three New Strength Tablets Approved by the FDA: 40 mg, 50 mg and 60 mg --

-- New Tablet Strengths Provide Additional Patient Convenience and Dosing Flexibility --

NEWTON, Mass., June 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that three new strength tablets for XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, are now commercially available. The availability of these additional strength tablets follows a U.S. Food & Drug Administration (FDA) approval on April 15, 2021. In addition to the original 20 mg strength tablets, XPOVIO is now available in 40 mg, 50 mg, and 60 mg strength tablets. XPOVIO tablets are available in seven different package sizes to help healthcare providers individualize the dosing and administration of XPOVIO based on patient needs. The additional dosage strength tablets may also increase patient compliance by simplifying their treatment regimen and reducing the pill burden experienced by some patients. With the introduction of these new tablet strengths and additional package sizes, there is no change to the efficacy and safety profile of XPOVIO.

2 JUN 2021


MorphoSys to buy Constellation Pharma for 1.7B which is 8 times 2024 revenue. KPTI is trading at 1.3x so 8x would be $56/share for KPTI which is in the ball park of Barclays' $60/share buyout price target. Current price: $9.02

Karyopharm CEO Spoke at Jefferies today. Excellent talk. Here's the replay:

Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

-- NEXPOVIO is the First and Only Nuclear Export Inhibitor Authorized in the UK --

NEWTON, Mass., June 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on May 26, 2021 the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization for NEXPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Conditional marketing authorization is supported by data from the positive Phase 2b STORM study, which evaluated selinexor in adult patients with heavily pretreated, triple class refractory multiple myeloma and was published in the New England Journal of Medicine (Chari, et al.) in August 2019. Under the provisions of conditional approval by the MHRA, continued authorization for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial and is subject to additional monitoring. This marketing authorization follows a similar authorization granted by the European Commission and valid in all 27 European Union (EU) member countries which was announced on March 29, 2021.

JP Morgan: "We see blockbuster commercial potential for Xpovio based on survey feedback from US oncologists."

28 MAY 2021 - Analysts expecting at least a double from here.

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “buy” rating restated by stock analysts at Robert W. Baird in a report released on Thursday,


Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

24 MAY 2021 - Old Wall Street Trick

Wall Street manipulators' old trick: bring the price down to a ridiculously low level, and fight hard to cap it there, to make weak investors think that's the fair price; and will keep the price there to see how many people will sell. When sellers run out, the price is bid up. That's where KPTI is now, imho, ridiculously low manipulated price. Therefore, I am *not* selling in mid-9's or even several dollars higher.

23 MAY 2021 - New Patent

Karyopharm got a new patent (first item on the list below followed by other recently patents).

substituted benzofuranyl and benzoxazolyl compounds and uses thereof

multicyclic compounds and uses thereof

hydrazide containing nuclear transport modulators and uses thereof

nuclear transport modulators and uses thereof

polymorphs of selinexor

nuclear transport modulators and uses thereof

substituted benzofuranyl and benzoxazolyl compounds and uses thereof

(s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer

methods of promoting wound healing using crm1 inhibitors

hydrazide containing nuclear transport modulators and uses thereof

multicyclic compounds and methods of using same

substituted 2,3-dihydrobenzofuranyl compounds and uses thereof

nuclear transport modulators and uses thereof

substituted benzofuranyl and benzoxazolyl compounds and uses thereof

20 MAY 2021 - Lot of Goodies

Tomorrow, 21 May is Annual Shareholder Meeting. Should be interesting to hear the new CEO speak from position of being fully in charge.

coming up in 2 weeks. The hedge fund short cartel who's been promoting distortions and disinformation about Karyopharm via their puppet doctors, is in for an unpleasant surprise at ASCO.

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

§ Sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2021.

I think it's fair to assume we'll have fireworks by ASCO. That's only 2 weeks away.

An astute shareholder friend wrote:

Interested to see RAS-mutant related study notes from abstracts today. Abstract 2 - "the data suggest that selinexor-containing regimens could be active in other RAS-mutant cancers" Abstract 8 - "Greater anti-tumor activity was observed in patients with RAS mutations despite the absence of high microsatellite instability and/or deficient in mismatch repair"

Karyopharm ASCO 2021 Select Abstracts

1. Title: Survival Among Older Patients with Previously Treated Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd) in the BOSTON study

2. Title: Effects of Weekly Selinexor, Bortezomib, Dexamethasone (XVd) Versus Standard Twice Weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM)

3. Title: Effects of Refractory Status to Lenalidomide on Safety and Efficacy of Selinexor, Bortezomib, and Dexamethasone (XVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Previously Treated Multiple Myeloma

4. Title: Oral Selinexor, Pomalidomide, and Dexamethasone (XPd) at Recommended Phase 2 Dose in Relapsed Refractory Multiple Myeloma (MM)

5. Title: Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Carfilzomib Nonrefractory Multiple Myeloma (MM) Patients

6. Title: Selinexor Containing Regimens in Patients with Multiple Myeloma (MM) Previously Treated with anti-CD38 Monoclonal Antibodies (aCD38 mAbs)

7. Title: Molecular Predictors of Response to Selinexor in Advanced Unresectable De-differentiated Liposarcoma (DDLS)

8. Title: Open-Label Phase 1 Study Evaluating the Tolerability and Anti-Tumor Activity of Selinexor and Pembrolizumab in Colorectal Cancer.

9. Title: Selinexor in Combination with Weekly Paclitaxel in Patients with Advanced or Metastatic Solid Tumors: Results of an Open Label, Single-Center, Multi-arm Phase 1b Study

10. Title: Updated Overall Survival of Eltanexor for the Treatment of Patients with Hypomethylating Agent Refractory Myelodysplastic Syndrome

11. Title: A Randomized, Open-label, Phase 3 Study of Low-dose Selinexor and Lenalidomide (Len) Versus Len Maintenance Post Autologous Stem Cell Transplant (ASCT) for Newly Diagnosed Multiple Myeloma (NDMM): ALLG MM23: Sealand

12. Title: U.S. Budget Impact (BI) Model for Selinexor, Bortezomib, and Dexamethasone (XVd) for the Treatment of Patients with Previously Treated Multiple Myeloma (MM)

13. Title: SIENDO/ENGOT-EN5/GOG-3055: A Randomized Phase 3 Trial of Maintenance Selinexor Versus Placebo After Combination Platinum-based Chemotherapy in Advanced or Recurrent Endometrial Cancer

14. Title: A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

15. Title: Digital Measurement of Functional Status of Patients with Glioblastoma

16. Title: A Phase 1b/2 Study of Selinexor in Combination with Imatinib in Patients with Advanced Gastrointestinal

Stromal Tumor (GIST): SeliGIST/GEIS-41 Trial

Selinexor Reduces Pain in Patients With Advanced Dedifferentiated Liposarcoma, Study Finds

New data show pain worsened faster, and more dramatically, in patients given placebo versus selinexor for dedifferentiated liposarcoma, as measured by the European Organisation for Research and Treatment of Cancer’s 30-item core quality of life questionnaire.

Patients with advanced dedifferentiated liposarcoma (DDLPS) had less pain and slower worsening of pain when treated with selinexor (Xpovio) compared with placebo, according to new data from the phase 3 portion of the Selinexor in Advanced Liposarcoma (SEAL) trial (NCT02606461).1

14 May 2021 - Big News Out of KPTI's Chinese Partner

Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies

"At this site, Antengene plans to soon initiate the manufacturing of selinexor, the company's first selective inhibitor of nuclear compound."

"At this new facility, we will begin the commercial manufacturing of selinexor in China to meet the future demands from patients.""

"efficiently supply high quality drugs to patients in APAC."

"As a novel therapy targeting a broad spectrum of tumor types, selinexor has demonstrated antitumor activity in multiple hematologic malignancies and solid tumors, and is already approved in the U.S. for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Antengene has submitted new drug applications (NDAs) for selinexor in China and multiple APAC markets, and expects to receive market authorizations during Q4 2021 and Q1 2022."

13 May 2021

Move your shares from Type2(margin) to Type1(cash). Call your broker and ask for the shares to be journaled to Cash - or open Type Cash account and move the shares there. This ties up shorts' hands.

Today I moved (journaled) a bunch of shares shares from margin account (type 2) to cash account (type 1). When in margin your shares are often lent out without you knowing. Or the shares don't even exist. You just have a marker in your account; phantom shares. But if you journal it to type Cash, the shares are recalled and shorts get the email they don't want to see: deliver!


§ Someone bought 7100 shares equivalent of January 2022 $20 calls betting the price will be over $20.60 by January.

§ Someone bought 21400 shares equivalent of June 2022 $10 calls betting the price will be over $10.45 by June OpEX.

Karyopharm/Antengene's selinexor application OK'd in China for endometrial cancer

China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for a Phase III trial to evaluate the safety and efficacy of selinexor (Xpovio) being co-developed by Karyopharm Therapeutics (KPTI) in the treatment of advanced or recurrent endometrial cancer (the SIENDO trial).

Antengene is currently conducting five late-stage clinical trials of selinexor for the treatment of MM, DLBCL, non-small cell lung cancer, and peripheral T and NK/T-cell lymphoma.

Antengene has submitted NDAs for selinexor in multiple Asia Pacific markets and was granted the Priority Review status by China's NMPA and an Orphan Drug Designation by the Ministry of Food and Drug Safety of South Korea.

May 2021


Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

12 May 2021


Selinexor data will be reported in 12 presentation at EHA meeting in June. One presentation is particularly interesting, "EFFECTS OF SELINEXOR ON PREVIOUSLY TREATED MULTIPLE MYELOMA (MM) WITH RAS-MUTATIONS"

Conclusion. Despite typically having the worst outcomes, pts with RASmut MM had a similar benefit from XVd as RASWT MM, showing that the XVd combination can overcome traditionally poor prognostic RASmut. Mechanistically, selinexor induced down regulation of GCK and enhanced killing of RASmut MM cells. With a manageable safety profile, the XVd regimen could provide a viable treatment option to improve PFS and OS in pts with MM with RAS mutations.


§ XPOVIO prescription (RX) demand increased 17% in Q1 2021 as compared to Q4 2020 following expanded FDA indication granted in December 2020

§ Over 160 new physicians / accounts prescribed XPOVIO for the 1sttime in Q1 2021

§ Ended Q1 2021 with $233.6M in cash, cash equivalents, restricted cash and investments

§ 16 abstracts selected for presentation at 2021American Society of Clinical Oncology (ASCO) Annual Meeting (June 2021)

§ Potential partners have also expressed a very strong interest in our solid tumor pipeline.

§ "As we're in the process of discussing and evaluating potential partners in Europe and Japan, with the recent marketing authorization, the EU, as well as the acceptance of the EMA for BOSTON indication, which is where we know much of our value to us, and potential partners will be generated, we need to continue to explore those partnership opportunities. And the immediate priority is around ensuring we bring XPOVIO to the EU and multi myeloma. However, potential partners have also expressed very high interest in our solid tumor pipeline." CEO Richard Paulson

11 May 2021

Drs. Shacham and Kauffman took a big salary cut and their stock options were forfeited

I respect Drs. Kauffman and Shacham deeply and have had zoom calls with both. Very genuine people. I'm not impressed with their management of Karyopharm but scientifically they're geniuses.

I have been concerned that change of guards might be symbolic and the status quo / founder's syndrome may go on but these filings tell me this change is fundamental, and I much welcome it. Good job Board of Directors.

Furthermore, as of end of the year, Dr. Shacham will no longer be the Chief Scientific Officer.

From KPTI Investor With 250,000 Shares

A friend who owns 250,000 shares of KPTI wrote me today:

"I didn't invest for a $20 or $30 buyout! I invested thinking $50 minimum. I'm genuinely feeling good about the company now."

KPTI insiders are buying in open market

Great sign. Two insiders reported today and yesterday of open market buys. Today report came that KPTI's Chief Medical Officer Jatin Shah just bought over 23,000 shares at around 8.60 for sum of $200,000. What an endorsement from someone in the know.

Yesterday one of the Board members bought in the open market.

Selinexor, Bortezomib, and Dexamethasone Combination Proves Effective for Myeloma

Somebody tell those bashers like Aaron Goodman and Vinay Prasad who have apparently had conflict of interest, to read this and weep: Fact is Selinexor is a great, life-saving drug:

“The BOSTON study is the first study to assess the efficacy of once-weekly selinexor as part of a triplet therapy in patients with multiple myeloma who have had 1 to 3 prior therapies,” said Joseph Mikhael, MD, in an interview with OncologyLive®. Mikhael is a professor in the Applied Cancer Research and Drug Discovery Division of the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center in Phoenix, Arizona

“The combination of selinexor and dexamethasone and bortezomib demonstrates synergistic cytotoxic effects in multiple myeloma in vitro, and increased antitumor activity in murine xenograft multiple myeloma models in vivo, including those resistant to proteosome inhibitors,” Mikhael explained.

“In the primary end point data, we can see that the SVd group demonstrated a sustained progression-free survival advantage over the twice-weekly Vd group with a 30% reduced risk of progression or death,” Mikhael said.

“Further, there was a consistent PFS benefit with SVd across multiple patient subgroups,” Mikhael added. “The risk of progression or death was noticeably lower in all subgroups including patients [aged] 65 years and older, those with high-risk cytogenetic abnormalities, and patients who received 1 prior line of therapy.”

“Patients in the SVd group also experienced significantly higher rates of deep responses than the Vd arm with 16.9% of patients experiencing a [CR plus sCR] and 44.6% of patients experiencing a VGPR [or better] as compared with 10.6% and 32.4% for CR [plus sCR] and VGPR [or better], respectively in the Vd group,” Mikhael said.1

“The median time to response was shorter in patients who were given SVd, [and] The duration of response was longer in the SVd arm,” Mikhael added. The median time to response was 1.4 months in the SVd arm and 1.6 months in the Vd arm; the median duration of response was 20.3 months and 12.9 months, respectively.

“Collectively, these findings suggest that SVd provides significantly higher PFS, overall response, and duration of response than Vd. Patients also experienced deeper and faster response than those not given selinexor,” Mikhael said.

9 May 2021 - Musings on New CEO, Buyout, Stock Action

Someone wrote: "I feel confident in the new CEO and the pipeline of products. A question in the back of my mind... What are the odds of being in a new CEO as part of an a coming merger? KPTI has the medications and the science and merger with a sister company or a sales team agreement could change it all."

The CEO has ties to several potential suitors. He has deep experience / relationships with the following companies:

§ He was the CEO of Ipsen North America, a global biopharmaceutical company focused on innovation and specialty care in areas of oncology, neuroscience and rare diseases. Ispen would be a good suitors. They have been expanding, and Karyopharm is a good strategic fit for them.

§ He was at Amgen for 10 years holding varying leadership positions across Europe and North America, including Vice President and General Manager of Amgen’s U.S. Oncology Business Unit, and prior to that served as the Vice President of Marketing for Amgen’s U.S. Oncology Business, General Manager of Amgen Germany, and General Manager of Amgen Central & Eastern Europe. There are several key words here that are extremely important to Karyopharm: Oncology, Marketing, and his deep experience in Europe is icing on the cake given Karyopharm recently obtained European approval and will likely get a second approval in a matter of months.

§ He held a number of global leadership positions at Pfizer Inc., including serving as General Manager of Pfizer South Africa and Pfizer Czech Republic.

§ He held a variety of sales, marketing, and market access roles at GlaxoWellcome in Canada. Again, full of key buzz words relevant to Karyopharm.

Any of these companies could buy Karyopharm (and there are more). Now, whether his appointment is tied to an existing nurturing merger situation, is a mystery to me. If anyone has the answer please share it with me.


The stock hit a new low last week to upper 7's, but rebounded nicely to mid 8's. There are 3 forces that can engaged in pressuring the price, aside from anyone who sells for personal reasons or in relation to indices.

§ Short sellers

§ Prospective buyers

§ Traders who sold and want to buy at lower price

§ Potential acquirers engaged in manipulating the shares (this is a documented fact that happens).

Except for the last one, the rest have a goal to buy the stock. The last one has the goal of just pressuring the stock. Of course it's risky business for them as manipulation is costly. I don't know the topic first hand but from a distance it seems that at some point any of these entities calls the bottom and starts buying.

And you can be sure, the regulators will be watching very soon. I have ties to FINRA and am making a massive report with documentation on the suspicious activity on the stock which FINRA will look. The last report we made, led to FINRA stopping the abusive manipulation (I had a couple of conference calls with them to help them out, following the report I and my friends wrote) - click here to see it.

A lot also depends on the company's execution. With the new CEO in charge I am relaxed about the company (I was nervous before due to founder's syndrome at the company). I just hope he's not a symbolic CEO and the founders are not pulling the strings from the background. Two big letters are being prepared by investors to the company.

Also IR has a key role. Some old-timers are not happy with Karyopharm's IR efforts, social media presence, etc. -- and there's evidence of ineffective handling in some of these areas. That's another area the new CEO to put under microscope.

6 May 2021 - Catalysts, Turnarond, Buyout Prospects

I'm excited about the rest of the year. There are a number of key catalysts coming up that can turn the KPTI universe around (for the better). Add to that a new CEO who has all the right relationships with big pharma. Just as the long-term shareholders who follow and know the company well have told me, I expect competitive bidding after solid tumor data later this year and the company getting bought out for a luscious premium.

6 May 2021 - Short Interest Freaking About New CEO

Shorts didn't like the CEO change. They probably viewed Dr. Kauffman as an ideal CEO because of his failures and lack of track record in building shareholder value. Mr. Paulson is a big threat to the shorts: he can shake the entire short thesis/paradigm. And this entire fake game shorts are putting on, in my opinion, with manipulating the price, could be a symptom that they're freaked about Mr. Paulson. It's conceivable that shorts break ranks with each other and start covering at any time and stock could rebound.

I've never seen a biotech or any company with such strong analyst endorsement be in a hole that Karyopharm is in (which is a result of mismanagement in my opinion). The science is not in hands of a competent CEO who's got everything it takes to make Karyopharm a success.

A large investor from the industry was telling me recently, when we were formulating the letter to the board, the kinds of qualities the new CEO must have. Mr. Paulson fits all of that.

6 May 2021 - Note on Manipulation

Tough day. I've been through a few of these before. Yes shorts can manipulate a stock. They're experts in managing (and ruining) investor psychology. They use all kinds of tactics with the stock and options to send weakness signal, to prompt people to sell so they can cover.

Another current here at play is potential acquirers who can engage in manipulating the stock so they can buy a company at a lower price. This is a well documented fact from industry insiders.

The key is whether the company's product/story has merit or not. Shorts succeed in ruining companies with a fluff product/story. KPTI's offering is absolutely solid. So in this case, shorts would want to cover. But they use index weakness, and events to manipulate the stock. It's their chance to drill into investor psychology. At some point strong hands remain, and shorts stop taking on additional risk. Manipulation is costly. Past mismanagement is the main culprit. But we have a new CEO. I'm very optimistic.

5 May 2021 - Advice from Billionaire Charlie Munger

"If you can’t stomach 50% declines in your investment, you will get the mediocre returns you deserve."

5 May 2021 - report to FINRA on manipulation of stock & options

Shorts are playing a dirty game that's probably unlawful. There are several clues to the shenanigans. I'll be filing with my contacts at FINRA shortly to investigate it. Last time we put a stop to abusive treatment of a stock.

5 May 2021 - New CEO is fully loaded

Richard Paulson is a beneficiary owner of 559,800 shares

4 May 2021 - Important Comments

§ During the first quarter of 2021, XPOVIO generated net product sales of $21.7 million, representing a 7% increase as compared to the fourth quarter of 2020 and a 35% increase as compared to the first quarter of 2020. Net sales for the first quarter of 2021 were largely driven by prescription demand from both academic and community-based oncologists for patients with multiple myeloma. Approximately 1,170 XPOVIO prescriptions were filled in the first quarter of 2021 as compared to approximately 1,000 prescriptions in the fourth quarter of 2020, representing a 17% increase in patient demand from the prior quarter. Further, over 160 new physician prescribing accounts were added in the first quarter of 2021, which included physicians treating both myeloma and diffuse large B-cell lymphoma (DLBCL). Additionally, prescription demand in the first quarter of 2021 was the highest generated since XPOVIO's initial accelerated FDA approval in July 2019.

§ Morgan Stanley reiterates Overweight opinion and $32 PT, citing the importance of prescription data trends over reported sales. "Prescription volumes for Xpovio increased 17% from 4Q20, with the recent approval of the BOSTON regimen being the primary contributor to the incremental growth. We continue to expect the drug to gain momentum and ramp sharply as the year progresses, with inclusion of the BOSTON data on the label."

§ New CEO is key. He worked at IPSEN on launch of EXEL's Cabometryx and knows EU mkt well.

§ ASCO June 4-8. Karyopharm will be there. Found abstract titles with Selinexor for 16 presentations at ASCO meeting next month. It shows a lot of interest to this drug from many investigators.

§ Weekly dosing is the norm and the combo with Kyprolis will add to its uptake in the Myeloma arena. Endometrial by next year and most likely Europe this year. Be patient and be an investor not a trader with this one. I would be surprised if we do not see 20s in the next 12 to 18 months. May not be what some want to hear but that is still a huge return. (Dollar cost average in on this one.) I know some thought this was going to $49. Sorry Baird but I would be surprised...... Best of luck team!

4 May 2021 - Good article: Karyopharm taps Amgen, Pfizer veteran as CEO

4 May 2021 - Tough day for KPTI and the markets but Karyo's story is solid.

Some of the most rewarding stocks I’ve owned put investors thought Chinese water torture before the big reward. Wall Street always wants to live and if retail holds shares and Wall Street is short shares, WS assumes it’s retail that has to provide the shares at the price WS wants. So, they grind the nerves of Main Street and they often succeed in getting Main Street to throw in the towel.

Today’s painful, exaggerated drop in KPTI is influenced by the same motive. The tough investors I knew who kept their shares through the tough times ended up doing real well as long as the company’s story is solid, and Karyopharm’s is a rock solid story. Just my 2- cents.

3 May 2021 - Morgan Stanley reiterated Overweight & $32 price target on KPTI.

Morgan Stanley updated KPTI minutes ago, MAINTAINING their Overweight rating and $32 PT. From the report: "While it is too early to determine the long term trajectory of Xpovio post the BOSTON approval, script data suggests that volumes are starting to inflect. This could bode well for the second half. We expect revenue will grow sharply as the year progresses as 1) the increased growth from the BOSTON regimen adds new patients and 2) the higher duration of therapy for this regimen will keep patients on drug for considerably longer. We remain above consensus on 2021 Xpovio sales ($162M vs. 146M), predicated on continued volume growth and stabilization of net price in 2Q21 and beyond."

3 May 2021 - Large Retail Holders

There are several large retail shareholders I know. One of them whom I know and trust, wrote to me today that he's upped his holding to 250,000 shares and is planning to hold. We're all happy with having a new CEO. I assume institutions have a similar sentiment.

3 May 2021 - Ipsen Pharma & Karyopharm -- & Pfizer

An insider said a few weeks ago (I heard today) that the Board has been very active (more active than he's ever seen in any other company) -- which is a very good thing -- and he won't be surprised if Ipsen Pharmaceuticals buys them because they want to grow their oncology business...and US footprint.

A few weeks later Richard Paulson became our new CEO. Mr. Paulson comes from Ipsen!! He was the CEO of Ipsen North America.

Ipsen buying Karyopham would be a good fit. I don't think they have the kind of money Drs. Kauffman and Shacham would like to get for the company. I'd guess Ipsen could offer 2 billion (which is around $26/ share). I'd be very happy with that.

A thoughtful friend and long term KPTI investor wrote to me today in response to that idea:

"Interesting, I screened Ipsen before after reading MK statements that they’d go with a mid cap (<$10B) or smaller European partner. Last paragraph-

And on the Feb call they mentioned they expect to announce the partner in the next few months."


PS -- Mr. Paulson also has deep ties to Pfizer. Rumor on weekend for PFE takeover of KPTI. Let's see...

3 May 2021 - NEW CEO / PRESIDENT -- !!!YES!!!


Time To Celebrate!! Congrats in particular to Drs. Michael Kauffman and Sharon Shacham for stepping down as CEO/President. A big overhang for the company and the stock is removed. Most founders don't have the insight and character of Drs. MK & SS to let go of leadership when it's time.

Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer

-- Richard Paulson, Recent Chief Executive Officer of Ipsen North America and Former Vice President and General Manager of Oncology at Amgen, Brings Wealth of Commercial Leadership and Global Strategic Experience --

-- Michael G. Kauffman to Remain on Board of Directors and Assume New Role as Senior Clinical Advisor--

Exactly the background you want for this role:

Richard Paulson

President and Chief Executive Officer

Mr. Paulson was appointed President and Chief Executive Officer of Karyopharm in May 2021 and has served as a member of Karyopharm’s Board of Directors since February 2020. He was previously an Executive Vice President of Ipsen Pharmaceuticals, Inc. and Chief Executive Officer of Ipsen North America, a global biopharmaceutical company focused on innovation and specialty care in areas of oncology, neuroscience and rare diseases, from February 2018 to May 2021. Mr. Paulson previously worked at Amgen for 10 years holding varying leadership positions across Europe and North America, including Vice President and General Manager of Amgen’s U.S. Oncology Business Unit, and prior to that served as the Vice President of Marketing for Amgen’s U.S. Oncology Business, General Manager of Amgen Germany, and General Manager of Amgen Central & Eastern Europe. Prior to Amgen, Mr. Paulson held a number of global leadership positions at Pfizer Inc., including serving as General Manager of Pfizer South Africa and Pfizer Czech Republic. Mr. Paulson also previously held a variety of sales, marketing, and market access roles with increasing seniority at GlaxoWellcome in Canada.

Mr. Paulson has an MBA from the University of Toronto, Canada and an undergraduate degree in commerce from the University of Saskatchewan, Canada.


Earnings Presentation

3 May 2021 - Pre Earnings Report Dynamics

Earning call at 8:30 Eastern today.

Pre earning reports dynamics:

§ Excellent Life-saving medical breakthrough

§ Regulatory derisked

§ Analysts very optimistic

§ Stock very undervalued

§ Ripe buyout target

§ Pharmas already knocked on their door

§ Suddenly lots of posts with very positive predictions (strange)


§ Stock is under the shorts' thumbs (because of a weak CEO, IMO, because management matters and KPTI's CEO is a great medical doctor but has no track record in running a successful business, not education in management, and he admits he doesn't have what it takes and wants to stop down (WHEN?)

§ It should be worth at least 2B today (and bought for at least 3B) is valued at 700M b/c of management issues which can be solved overnight with the founders stepping down from CEO/President role.

Some investors have written that they're expecting the worst but are hoping for the best. If they just release bad numbers and the same dysfunctional management continues and they don't tell the public same things they told me (new CEO, not go it alone, etc.), then the stock could temporarily tank. Given the strength of the science it'll be a great buying opportunity , so I expect it'll rebound.

If they add good news like new CEO, partner..., stock will take off.

No matter what, I will hold my shares because I know, with a new competent CEO the company can get fairly valued and that's at least $22/share. I can wait.


In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics (KPTI), with a price target of $49.00.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Karyopharm Therapeutics with a $29.25 average price target, representing a 184.0% upside.

In a report released yesterday, RBC Capital also reiterated a Buy rating on the stock with a $24.00 price target

Published On: Tue, 30 Mar 2021 10:15:00 GMT

Being at $9.30, a $49 price target seems unrealistic but I have personally seen analyst be right with such projections. I owned a biotech at 2.50, analysts had 7, 12, 15 targets for it that seemed so unrealistic. It was taken over at $17 and an army of shorts got crushed.

2 May 2021 - Earnings Call

3 May the company is having its quarterly earnings call. I am hoping they tell the investors what they told me -- the public deserves to know it -- that:

1) The company no longer wants to go-it-alone. CEO Dr. Michael Kauffman has said on a number of occasions that they want to go it alone. In December 2020 he said they can be the next Celgene. [by the way, when I see a Medical Doctor as a CEO that's always a red flag for me -- but in my doing due diligence on Karyopharm I missed that because I was so mesmerized by their amazing science]. They need to make it clear to Wall Street that they are open to being acquired. CEO told me they've had interested parties but they told them "not yet". But now it's time they are open to overtures. I told him blundly, with all due respect, I don't trust him with negotiating with Big Pharma (I just don't see that talent in him). He said some senior board members get engaged in such talks. We still need a strong business-minded CEO to lead such discussions.

2) The CEO wants to step down because he doesn't think (rightly so) he's fit for that role (he has no commercial experience, he has no experience building shareholder value, and prior to Karyopharm, he never had a CEO role that was successful for shareholders, and all his other experiences were medical/scientific. So clearly the wrong profile for this stage of the company's growth, and he knows it, Thank God.

But between him and his wife, Dr. Sharon Shacham who is a celebrity in biotech (they're both geniuses in my opinion and I highly respect both of them), who is serving as president and CMO, they've got the company stuck in a case of founders syndrome. They need to relinquish their CEO/President position and the stock will take off. Shorts love scientific founders who fail shareholders at CEO.

So those announcements will boost the stock.

Regarding earnings, I think the numbers will be poor because of Covid and because of management issues. Management matters, and impacts all aspects of a company's business, including dealing with currents that impact sales. This was elaborated in detail in a letter we sent to the Board. But I'm hoping other news will offset the poor sales. And I'm really hoping we don't get excuses and rationalizations because the key issue (and risk) is, as the CEO himself admitted, him being in the wrong role. And he's told the Board. So the Board has a duty to act quickly on that. Let's hear the news.

A main Issue in founder's syndrome is such nice ideas are often lipservice because deep down the founder finds excuses to continue – kind of like being addicted to smoking. Smokers always defers quitting for a future date that never comes. It's called psychological time. See my article.

1 May 2021 - Multiple myeloma triplet therapies: baseline characteristics and control groups

26 Apr 2021 - J.P.Morgan very bullish on kpti-- it expects 125% return in next 8 months.

In a new report, J.P.Morgan reiterated their Overweight rating, with $21 price target for December 2021, citing catalysts that could change that picture, e.g., data readouts later this year. "Summary Investment Thesis and Valuation We are rated Overweight on KPTI shares. Following recent approval of the BOSTON label expansion in earlier-line MM and a positive CHMP opinion in the penta-refractory setting, we see blockbuster commercial potential for Xpovio based on survey feedback from US oncologists. Further, we see further optionality in DLBCL and other solid tumor indications, all under-reflected by current share levels."

"With the phase 3 SIENDO study ongoing and topline readout expected by year-end 2021, a 2-3 month benefit on mPFS (HR of 0.6) could be viewed as clinically meaningful. Accordingly, our model now includes risk-adjusted peak forecasts in endometrial cancer of ~$200M with50% POS."


Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO® (selinexor) in Combination with Velcade® (bortezomib) and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma

- EMA Regulatory Decision Expected in the Fourth Quarter of 2021 -

About Multiple Myeloma in Europe

Multiple myeloma (MM) is an incurable cancer with significant morbidity and the second most common hematologic malignancy. In 2020, there were approximately 51,000 new cases and 32,000 deaths from MM in Europe1. While the treatment of MM has improved over the last 20 years, and overall survival has increased considerably, the disease remains incurable, and nearly all adult patients will eventually relapse and develop disease that is refractory to all authorized anti-MM therapies. Therefore, there continues to be a high unmet medical need for new therapies, particularly those with novel mechanisms of action.

About NEXPOVIO (selinexor)

NEXPOVIO, which is marketed as XPOVIO® in the U.S., is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine. NEXPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1). NEXPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion. NEXPOVIO (selinexor) has been granted conditional marketing authorization by the European Commission in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

22 Apr 2021 - NEW TRIAL WITH

Karyopharm today initiated a new clinical trial with selinexor in combination with Bristol-Myers Squibb Opdivo (nivolumab) and Yervoy (ipilimumab) for patients with advanced solid malignancies.


"The Phase 3 SEAL study suggests that selinexor has enhanced clinical activity and a manageable safety profile in patients with DDLPS, a very rare and aggressive form of cancer where there are very few treatment options available. In addition to meeting its primary endpoint with a statistically significant improvement in progression-free survival (PFS), treatment with selinexor also resulted in improvements in key quality of life parameters as compared to patients treated with placebo," said Jatin Shah, MD, Chief Medical Officer of Karyopharm. "The results highlight that the reduction in tumor growth, as measured by objective radiographic PFS, is accompanied by clinically important reductions in pain, with minimal effects on other aspects of quality of life. Since pain is one of the most devastating symptoms associated with advanced and progressing DDLPS, the significant reduction in pain, and a delay in the time to definitive deterioration reported by patients in the selinexor arm, combined with the convenience of an orally administered therapy, could represent a meaningful clinical benefit to patients."

"We are pleased to see the first set of data from the Phase 3 SEAL study now published in a peer-reviewed medical journal," said Sharon Shacham, PhD, MBA, Founder, President and Chief Scientific Officer of Karyopharm. "These data continue to support our overarching development strategy to pursue additional solid tumor indications where we believe selinexor can demonstrate meaningful clinical activity both as a single agent, and more importantly, as part of future combination regimens for patients battling cancer."

18 Apr 2021 KPTI musings


A large investor wrote:

Thanks Reza. I’ve been doubling down and buying more kpti shares. I really believe in the science and hope we are all soon rewarded as shareholders. Have a good day!


KPTI is being held down by the founders who are scientific geniuses but have been a failure in building shareholder value. I've been busy (not that I've been looking for things to do) in digging into the KPTI story. It's well worth it because

§ The science is amazing, unique, and it saves lives.

§ The stock is very undervalued. Average analyst estimate is $30.

§ Short interest has been in control because of weak leadership - so a change in leadership can quickly turn the stock around.

§ Short thesis is weak, and backed by a couple of rogue doctors. We've found hot tips on this topic and are investigating it.

§ The CEO agrees he's not fit for the job - we expect a CEO change soon, like immediately hopefully.

§ I'm not expecting a strong quarter but am expecting good news, like CEO stepping down, and maybe EU partnership.

§ Rich pipeline; lots of irons in the fire.

§ Prime buyout candidate. Mismanagement has failed to build necessary relationships (e.g. sales synergies), and big pharma is probably pulling some strings against the stock to help it buy the company for cheap. The missing piece is a strong CEO who can grab this bull by the horn. I'm very confident that a strong new leader (and full, complete relinquishing of power by the miserable current leadership) can execute a sharp turnaround where the stock quickly goes to upper teens, followed by a buyout in the 30's or 40's. I know investors (and analysts) who think the buyout price should be even higher, but I will be very happy with $30 or $40. Barclay projected $60 buyout price.


You have to look at the big picture my friend.

1) Management matters - otherwise why not make the janitor as the CEO and save a ton of money.

2) Management being inept in building shareholder value makes the company prime target for shorts because they know management will fuck up shareholder value. of

3) A competent CEO can do a lot, trust me. And an incompetent one (in running a business not a charity that enriches the founders, as we've seen can ruin shareholder value. Incompetence in that area has many consequences and we've seen an whole array of consequences. A CEO competent in making a business a success can right all those wrongs.

4) Michael Kauffman realizes the problem and wants to step down. Outside forces can just help expedite the transition out of a rotten status quo.

5) Dr. Kauffman being the CEO is the single biggest risk about this investment, in our opinion.

6) Yes, weak leadership, inept in managing the market, does effect the demand channel as well when you understand the deeper currents.

7) I don't agree with your idea that MK won't be replaced until a buyout. I don't trust him negotiating a buyout, or anything for the matter.


RBC Capital Thinks Karyopharm Therapeutics’ Stock is Going to Recover.

RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI) on April 8 and set a price target of $24.00. The company’s shares closed last Friday at $10.02, close to its 52-week low of $9.75.

Currently, the analyst consensus on Karyopharm Therapeutics is a Strong Buy with an average price target of $30.40, representing a 201.9% upside. In a report issued on March 30, H.C. Wainwright also maintained a Buy rating on the stock with a $49.00 price target.

8 APR 2021 - American Association for Cancer Research

11 poster presentations on 10 April.!/9325/presentations/Selinexor/1

§ 1049. Optimizing the treatment schedule of selinexor in combination with decitabine in AML

§ 1058. Inhibition of nuclear transport protein XPO1 potentiates the effect of KRAS G12C inhibitors

§ 1061. Characterization of synergistic selinexor combinations with dexamethasone, pomalidomide, elotuzumab, and daratumumab in primary MM cells

§ 1091. Nuclear export inhibitor KPT-8602 synergize with PARP inhibitors in castration resistant metastatic prostate cancer

§ 1228. Novel small molecule inhibitors that target the exportin binding pocket of TOP2A for the treatment of multiple myeloma

§ 1341. Inhibiting the nuclear exporter XPO1 and the antiapoptotic factor BCL2 is synergistic in XPO1 and SF3B1 mutant hematologic malignancies

§ 1380. Synergistic effect of the combination of XPO1 and mTORC1/2 inhibition for the treatment of triple-hit DLBCL

§ 2383. Mir-7974: An oncogenic miRNA that perpetuates gastric cancer

§ 3040. Inhibition of Exportin-1 as part of combinatorial treatment for patients with high-risk neuroblastoma

§ 738. Targeting metabolic vulnerabilities of endocrine resistant breast cancers using XPO1 and NAMPT inhibition

§ 994. Investigating inhibition of nuclear export in breast cancer cells


I think we should assume Q1 numbers will suck due to Covid and management issues. In my talks with the President and CEO they both reiterated how great the drug is, and I believe it. A couple of doctors are bashing the drug but they're probably also consulting for hedge funds :-). The drug saves lives!

I'm looking beyond Q1. To change of leadership which MK told me is coming because he knows his limitations and he believes they need a CEO with a different skillset than being a good doctor.

New CEO announcement will rattle the shorts who are counting on the founder's syndrome that's bogged the company down, and it's not just about lack of commercial skills.

Rich pipeline. Looking forward to more positive data. MK also said they are now open to selling the company - that there were suiters in the past but they told them "not yet" but now is the time. Let the competitive bidding begin. I think Karyopharm will be bought within the next 12 months. And I'm willing to wait.

6 APR 2021 - News & analysts

Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma... ATG-019 is a global first-in-class oral dual PAK4/NAMPT inhibitor developed by Karyopharm Therapeutics Inc. (NASDAQ: KPTI). Antengene reached an exclusive agreement of cooperation and authorization with Karyopharm and obtained the exclusive development and commercialization rights of ATG-019 in multiple Asia-Pacific markets, including Greater China, South Korea, Australia, New Zealand and ASEAN countries.


4 APR 2021 - URGENT NEED FOR NEW CEO; current ceo agrees change is needed

Last line: "As a company, Karyopharm has great drugs and great technology with really no competition at the moment so we truly have the potential to become the next Celgene."

That was in 2020. A very delusional statement of a CEO who has no background business/commercial world and no education in it either. A great doctor/scientist. Karyopharm urgently needs a new CEO. Like yesterday!

He said the same thing in 2014: we will go it alone. Recently he told me he no longer sees that as a good option and thinks the company will be better off if it's sold. Suiters had come before, company said not yet. But now they're talking again, IMO, based on what I read between the lines. That the board is involved in it. But I told him I don't trust you negotiating a deal, as much as I like you as a man of integrity and a great doctor/scientist.

He also said he agrees with me and sees his shortcomings and has told the Board. But that means it could take months due to inertia of status quo, while urgent action is needed, which may mean an interim CEO.

Amazing science in hands of a top notch well-qualified businessman/salesman/commercial-guru CEO will make KPTI value go to the moon. This is the opinion of several investors in KPTI who hold a significant number of shares. And Dr. Kauffman seems to agree. But where's action?!

2 APR 2021 Letter to board

Appendix 3 (Final Addendum) went to the Board citing intelligence from a Big Pharma, and other tips.


Hi Folks

KPTI got European approval.

§ NEXPOVIO is the First and Only Nuclear Export Inhibitor Authorized by the European Commission

§ Second European Regulatory Filing Based on Phase 3 BOSTON Data Expected by April 2021

The stock is heavily manipulated by shorts because of founder's syndrome, IMO. But analysts continue to be very bullish. The company just received EU approval. 3 analysts I know of commented last week:

- In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics (KPTI), with a price target of $49.00. The company’s shares closed last Monday at $9.85, close to its 52-week low of $9.79.

- Morgan Stanley notes conditional approval, and reiterates their price target of $32.

- Karyopharm Therapeutics (KPTI) Current Valuation Underestimates Xpovio Benefit - RBC Capital. RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $24.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI)

A number of new investors have been added to this mailing list including some with millions of dollars of investments in KPTI. Welcome. I had several discussions with the CEO, and the President (video, and via email). And have also been in touch with the Board of Directors. A big letter was sent to the Board that some of us worked on.

I had a good 30 min Zoom chat with the CEO/co-founder, Michael Kauffman. I really like him and think he's a honest man and has integrity, and he's a scientific genius. I also had a Zoom call with his wife, Dr. Sharon Shacham who invented the company's lead drug. She's also a genius, and she's nice and a woman of integrity. She also said they realize the issue (that the founders have reached their competence limit for taking the company to the next level).

said: "I am more on your side than you know." He shared my sentiment that the company needs a new CEO. He essentially told me he knows he doesn't have the competence to be the CEO and has informed the Board. He quoted Clint Eastwood "man must know his limitations". "I can assure you that this discussion is being had with the board. Right now. and I am admitting it to you because I am with you, I'm a straight shooter".

Sounds great but it needs to happen sooner than later. Point of our letter was to outline why the transition has to be expedited. It's a classic Founder's Syndrom many of you are familiar with from some previous stocks we've discussed. But it's great that the founders in this case realize their shortcoming.

The consequence of mismanagement is best reflected in the share price. I truly believe good management can turn the company around. The CEO even cited a case where the CEO was changed and the stock took off. He pointed to the heavy weights on the Board, with experience building a 16 billion dollar company, for example, who are engaged in key talks.

The CEO also told me they had pharma interested in buying them but company told them not yet. I suppose they're back in play. Consensus is KPTI will be bought out. I told him that with all due respect I don't trust him negotiating a deal :-) He agreed :-). They have heavy weight board members. He made it very clear he's willing to let go of the "baby". I can't wait!

I anticipate change of leadership hopefully soon. If you are invested, your feedback to the Board will help because my concern is the inertial of status quo. So rattling the cages can't hurt. Let me know if you need help with that.

He assured me that the money they're spending is attached to detailed NPV analysis and they expect to have 10 times return on that investment!

Much more can be found on my page on KPTI:

This is not an investment advice. To be removed reply with remove. I don't add these disclaimers to every mail as y'all know them already :-)

Happy to hear your thoughts.

Happy Easter



- In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics (KPTI), with a price target of $49.00. The company’s shares closed last Monday at $9.85, close to its 52-week low of $9.79.

- Morgan Stanley notes conditional approval, and reiterates their price target of $32.

- Karyopharm Therapeutics (KPTI) Current Valuation Underestimates Xpovio Benefit - RBC Capital. RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $24.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI)

My current outlook:

§ I'll be surprised the company is not bought out before year end. Matter of how much not if. $20, $30, $50? $60 a share? Remains to be seen.

§ I expect and hope an immediate change in top leadership, with a top-notch CEO who's Wall-Street-smart, and strong track record in commercial, business, sales, alliances, relationships, building shareholder value.

§ Quarterly sales may be weak but with right management of the entire enchilada (company, market, investors, enemies, etc.) sales will improve. But new management is a must.

31 Mar 2021 - Letter to the board

I sent a letter to the Board on behalf of the activist investor group.

Received feedback today:


Hi Reza-

Our Management Team as well as our Board of Directors have received your letter.

We of course welcome feedback from our shareholders and appreciate your detailed thoughts.

If there are any follow-up questions from our Board, I will certainly let you know.

All the best-


Dr. Sharon Shacham, PhD, MBA; Dr. Michael Kauffman, MD, PhD

Good. No options expiring for Sharon and Michael till 2023.


Some investor sentiments:

"long term play. Solid science. The SP will eventually get there with sales and new indications coming in solid Tumor. I strongly predict bo of 70-125 in next 3 years. No bs."

CC transcript: "We are having a number of discussions right now, both internally and with external partners on the best way to leverage that opportunity with the pending BOSTON indication that should come hopefully by the end of this year."

I still think a molecule with this profile would be worth at least 2x current market cap to a larger pharma company.

This stock is following in Regeneron's footsteps. REGN went down consistently for 4-5 weeks, either on good news or on no news. Go figure. (It went from 14 to 470).

The only reason this news is very good is bc getting Boston approved in Europe now went from a year review to just 4 to 6 months. It is easier to pass a SNDA than it is just NDA. That could bring a suitor faster who now can ramp Europe in 2021 perhaps

Don't get trapped by shorts' stupid arguments that are for purpose of bashing the stock and getting people to sell. Just like last week they were lying about the sales force. Fact is, KPTI should be trading 3 times higher, and it will. Just a matter of at what price the big shorts will choose (or be forced) to cover. Clock is ticking on them.

Would love to wake up to a $35 BO manana

Buyout is not a matter of it but when, and how much. I bet it will be this year, whether short sellers like it or not. So the window is closing.

expecting $BMY to help accelerate the pipeline and eventually take them out. Strategically this makes sense as $BMY is developing the same pipeline indirectly in APAC (except Japan) through investment in Antengene (via Celgene investment). Celgene brought CART assets from Juno into $BMY, and might also indirectly bring in valuable XPO1/CRM1 inhibitor assets from $KPTI while also enabling breakout expansion in APAC through Antengene. Regulatory and commercial constraints would make this path for $BMY and $KPTI hardly possible, but from among a thousand ways to fail the right leadership should find a few ways to succeed.

The safest (derisked bio) in my portfolio.

$KPTI I think post-COVID that the government will bring focus to cancer research, treatments, and lift the profile and value of many oncology companies. If you research around Eric Lander who is in the news recently you will see he cofounded $VSTM where Michael Kauffman ($KPTI CEO) is on the board, and they both were on the board at $INFI a few years ago. And way back they also worked together at Millenium, which Eric founded. And when Eric Lander’s appointment (to lead the Presidential Council of Advisers on Science and Technology and the Office of Science and Technology Policy) was announced at a Pfizer facility a month ago, Mikael Dolsten was acknowledged as a founding member of Cancer Moonshot- he has been on the $KPTI board for 6 years and is Head of Research at $PFE. All of these people have a great track record with solid science that’s produced great medicines. Just some observations. Small world, no? I’ll continue to be patient with $KPTI

drug is great...pipeline is super strong.

I have owned 10 bagger nbix and they have failed repeatedly clinically but they have one commercial homerun and the stock ran from 20 to 130 after revs took off

I think the first quarter numbers will not be good, given Covid, and Kauffman as CEO, and what short interest can do to hurt the sales. But I don't mind being pleasantly surprised. But I'm looking beyond quarter one. With change leadership everything can get better. I'm a big believer in the art and science of management.

30 Mar 2021 - EUROPE APPROVED - and earlier than expected.

Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

-- NEXPOVIO is the First and Only Nuclear Export Inhibitor Authorized by the European Commission --

-- Second European Regulatory Filing Based on Phase 3 BOSTON Data Expected by April 2021 --

26 Mar 2021 - KPTI CEO's remark

The good news is he does NOT want to go it alone

"Our kid is ready for university, and we want to send him to an Ivy League." Michael Kauffman, CEO, Karyopharm, March 24, 2021. This is one of many interesting notes I picked up from the talk with Dr. K. Have to find time to type the rest of my notes.

I read a lot into the statement above in the context out of discussion with me basically pressing that we need a CEO with business forte, and he agreed and said he's talked to the Board because he recognizes his own shortcomings (he's a phenomenal scientist who's gotten approval for 3 drugs and he's really good at that). So I think a new CEO is on the way, if the company is not sold by then.

Going to university here tells me more than founders recognizing a different caliber of leadership is needed to take their baby (company) to the next level (good they realize that). To my mind, the university analogy is a very interesting analogy that depicts selling to a Pharma, and Ivy League adjective was icing on the cake ;-)

That is a sharp contrast to "We want to go it alone" that he said in 2014.


From IR:

"Sales force is around 70 which includes traditional sales reps and also a handful of what we call “Nurse Liaisons” who focus mainly on medical education. We have not changed the size since we launched last summer."


We are kicking off a KPTI activist investor group. I haven't reached out to the mailing list of about 200 investors. Some of us have been together for a long time and formed activist investor groups in the past and we were very effective. For example, we were instrumental in getting a Board of Directors of a Biotech, fire the CEO (who was buddies with the board and it was his board), fired, and disgracefully so, because he suffered from Founders' Syndrome and was not willing to let go of his "baby" and have it managed by more qualified professionals.

$KPTI "Our kid is ready for university, and we want to send him to an Ivy League." Michael Kauffman, CEO, Karyopharm, March 24, 2021. This is one of many interesting notes I picked up from the talk with Dr. K. Have to find time to type the rest of my notes.

I read a lot into the statement above in the context out of discussion with me basically pressing that we need a CEO with business forte, and he agreed and said he's talked to the Board because he recognizes his own shortcomings (he's a phenomenal scientist who's gotten approval for 3 drugs and he's really good at that). So I think a new CEO is on the way, if the company is not sold by then.

Going to university here tells me more than founders recognizing a different caliber of leadership is needed to take their baby (company) to the next level (good they realize that). To my mind, the university analogy is a very interesting analogy that depicts selling to a Pharma, and Ivy League adjective was icing on the cake ;-)

We have many tools at our disposal, including getting institutions to join us as activist investors (in the past we successfully did this too), and Board members themselves who may be sympathetic to our cause, or may act out of obligation (fiduciary duties), and last resort: legal action (e.g. derivative lawsuit).

Of course best is to always take the friendly path, which is the best and most effective, and should work when dealing with highly intelligent people. Only roadblock is ego and attachment and other psychological shortcomings, but I am cautiously optimistic, we can be an agent of positive change, and friend, rather than an adversary.

If you're an investor and like to join us, feel free to email me via this page's contact page.

Best Regards

Réza Ganjavi, MBA


Also, with regards to financial shenanigans manipulating the stock and options, or spreading lies about the company. You should be very careful, because we're going to kick your ass if you step out of line. We've worked with the regulators before and brought shenanigans to justice. One is in federal prison as we speak.

23 Mar 2021 - KARYOPHARM value

800 million dollar valuation is dead cheap for a company with a great approved cancer drug with a unique, new, first-in-class mechanism of action, that can be used in various cancers, and cancer rates are going up. So what gives? (see my note below on stock price). What's the fair value? I think three billion is minimal which is $40 a share. That's why Barclay has a $60 acquisition price target.

23 Mar 2021 - KPTI Stock Price

800 million dollar valuation for a company we say incredible canceled it's going to be used for other cancers as well which can be used to multiple cancers let's say dead cheap. So what gives? What's the fair value? I think three billion is minimal which is $40 a share. That's why Barclay has a $60 this year target for acquisition.

What happened to the stock price the last 2 days? You never know but reading the tea leaves, this radical drop in the stock price could be related to some factors, none of which are the core of Karyopharm story: the science -- so that's the good thing.

Many FDA PDUFA event traders didn't know that FDA approved the drug 3 months early, back in December 2020 (rare for FDA to do that and shows how important the drug is, and how much FDA likes Karyopharm's science). So the traders who buy FDA decisions bought in the days leading to last Friday, and when there was no news, they sold on Monday. I believe that may have been a reason for the big drop yesterday despite a strong biotech market day.

Then today, we heard of a couple of fucking 10b5-1 (planned sales) by the CEO and President, 4000 shares each. They still have over 1.6 million shares worth almost 18 million dollars. Michael Kauffman and Sharon Shacham will be rolling in dough when the company is sold at $40 a share which is the minimum price I see as fair. They'll have 64 million dollars! Planned sales (10b5-1's) are not extraordinary but they suck. I advised Michael and Sharon to immediately stop the planned sales, esp. in light of the fact the stock has been under short attack.

So we had that today, and a weak market day, so the stock dropped more. I sense that probably market makers took advantage of this drop and took out some stop loss orders. Watching Level 2 a bit, the stock was dropping on very thin volume.

Another factor is founders' syndrome which impacts everything. But that can change overnight.

These are the factors I can think of aside from the bigger question of why there is a big short interest and I have two theories around that topic. Sharon confirmed with me in our talk recently that it can't be because of the science. That's how strong she feels about the science. So what else could it be? I believe it could be a suitor who is having the stock manipulated so they can buy the company cheaply. It is also probably related to some management issues. I'm addressing those with Michael on a call tomorrow. I offered them some free management consulting which is my profession, and of course, I do not want to, and I will not, receive any insider information.

I have been buying more shares of KPTI yesterday and today.

22 Mar 2021 - analyst are very bullish

18 Mar 2021

Mailing to my investors mailing list (not investment advice)


§ I had a 30 min zoom call with the president, Dr. Sharon Shacham. She's amazing. I'll edit the video and post more details as soon as I find the time.

§ New long positions were opened this week for April 20 and 22 calls (betting price will double next month!)

§ I suspect European approval will come in the 3 weeks. They have the CHMP thumbs up already and most drugs who get that get approved. I suspect EU partnership or RoW partnership will come unless the company is outright sold.

§ Swissmedic filing is in progress.


"Reza,Just wanted to re-mention ALDX. I think the stock is trying to base. Company has some readouts within the 2021 year (which of course we would need positive results), Leerink just initiated a $22 price target"


They got CRL from FDA. Stock lost 50% of its value


VYNE now has options available.


Dr. Joe wrote: Sold all my VYNE at a <big> loss so that I could put the money into BCRX. They report on their oral Factor D inhibitor on March 22nd. If follows through earlier results can be best in class oral factor D inhibitor (complement pathway - many possible indications) on the market. Current market cap under $2 billion with multiple approved products.


§ Re: Olorinab, following the data JPM says company won't pursue it further. SMBC just released note saying they will not pursue it alone. So more clarity on that. They will look to partner it.

§ Even some most loyal longs are now turning on Amit Munshi. Dr. Joe wrote:

"These are the trials that Amit is responsible for the failure of:

E- Pyoderma gangrenosum

E- Primary biliary cholangitis

E- Atopic dermatitis phase 2 trial

Visceral pain olorinab phase 2a trial

Visceral pain olorinab phase 2b trial

Why would you want keep rewarding failure and then turn this guy loose on the future of this company? Time for the board to start the sale process."

§ People are still criticizing Arena's IR :-) Perhaps leftover of inept Jack Lief era IR we tried to warn them about / organizational memory, power of status quo...

§ Amit Munshi said years ago when all the cards have been turned over he'll think getting bought, but I wonder if they're really open to it given they're all in lucrative comfortable positions -- probably another company habit from Jack Lief who ran the company to the ground with mismanagement and founders' syndrome.

§ I wish Arena success. Long-suffering shareholders deserve it.

13 Mar 2021

- On Friday, I did an interview / discussion with Karyopharm's genius President / CSO. Details coming up...

- International interest in Karyopharm stock: my page gets a lot of visitors from all over the world. Just today: USA (various states), Australia, Germany, Israel, UAE, Hong Kong, Italy, Canada, Singapore, Poland, France, Switzerland.

- There is no PDUFA next Friday. No major event next Friday that we know of. Don't count on it. The approval came 3 months early in December 2020 which is very unusual and very positive; shows FDA thinks very highly of the drug. I've never seen FDA approve a drug 3 months ahead of PDUFA date.

10 Mar 2021 - partnership

-Expanded Partnership with Medidata Supports Karyopharm’s Mission to Develop First-in-Class Therapeutics

6 Mar 2021 - KPTI UPDATE

§ I have a call scheduled with a Karyopharm's senior executive. If any of you have any questions, please send them to me via email or contact page of this site.

§ is very informative and also lists the company's tweets on the first page (very handy).

§ Understanding the Biology of Your Cancer: Four experts discuss "New Therapies Target Multiple Myeloma's Biological Drivers"

§ Karyopharm's President, Founder, & Chief Scientific Officer, Sharon Shacham joined @PharmaVOICE on the entrepreneurs panel at the Women of the Week Virtual Event with some of industry’s most influential women!

4 Mar 2021 - SIENDO TRIAL

Phase 2 data:

SIENDO phase 3 readout is later this year. This could be a game changer for endometrial cancer.

"We are very excited that the SIENDO study has passed its planned futility analysis and that the study will continue as planned," said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. "We believe this is an encouraging development for the study, and more importantly, for patients and families in need of novel treatment options for advanced or recurrent endometrial cancer. There are currently no approved therapies in the maintenance setting for patients with advanced endometrial cancer, making the future trial results from the SIENDO study, particularly important. We expect to report top-line data from this study in the second half of 2021.


The stock took a dive with the rest of biotech sector. But I feel absolutely confident for my own investment purposes. Karyopharm generates revenue, its target market has just expanded, it has a strong pipeline, strong IP, EU approval should come plus partnership, Barclays Global Healthcare Conference presentation next Tuesday. And on top of my investment thesis list is:


I firmly believe Karyopharm will be bought by a big pharma in not too distant future at a nice premium. Waiting for the press release any day, but I can wait.

27 FEB 2021 - Discussion with Ian Karp, Karyopharm's Senior VP of Investor & Public Relations

§ I am always thrilled to see biotech companies understand the importance of IR and put a senior, credentialed professional in charge of it. Companies that do that are rewarded by better investor relations, let's say, than those who don't. I can cite a number of examples that clearly distinguish between great, mediocre, and inferior IR. I think Karyopharm is in the first category.

§ Ian is an MBA (like me, haha). Aside from leading IR, he's trusted with the entire realm of corporate communications including financial communications, corporate visibility, media relations. Again, this tells me that company's leadership takes this matter seriously, and that's excellent. Many similar companies think of IR as an inconvenience, or have it in mediocre hands, or some outsourced joint which is spread extremely thin and provides little more than lip service.

§ Ian comes from Shire which was a big pharma acquired by Takeda in 2019, but while at Shire, Ian was engaged in acquisition strategy that led to over $40B in acquisitions. I assume he'd be a good negotiator when Karyopharm will be negotiating getting bought out by a big pharma (my guess: by end of this year, for several multiples of current price). Mind you average analyst target is double current level, with some triple current level, and acquisition price set by Barclay's is $60/shares. Stock currently: $14.5

We had limited time so we went quickly over some topics. Soon after, the same day, the company appeared on a fireside chat with SVB Leerink which was very interesting (link:

Short interest

We asked Ian about the short interest that's very high (20%) yet analysts are all very optimistic. Usually when there's a big short hedge fund, there's an equity research firm that's prostituting for it -- seen this many times in the past on other biotechs, where a weasel analyst sets a $1 price target on a stock that's trading at $4 to help push it down, and his big short client covers and the same short goes long by the time the stock is $50.

In KPTN's case, Ian suspects the short could be the holders of the convertible debt who would do that as a hedge: if stock goes down they profit, if the stock goes up, they're hedged by the convertible debt, and make the coupon. Makes sense.

I was wondering if there's an adverse even the shorts are waiting for. The hypothesis above discards that notion. So that's no issue. Also, having watched the stock behavior, it behaves differently than an active aggressive short trying to keep it down by drip selling, putting fake offers, getting media to prostitute for them by writing trashy articles, etc. -- I/we haven't seen that with KPTN's stock behavior, which attracted me to it.

There's been a trend to short biotechs which have launched during the pandemic. Some hedge funds are required to be short a certain %, and they're often long development stage biotechs for hopes of big gains on positive data move. So they short commercial companies whose launch may be hurting due to Covid-19. At some point that unwinds and the trend changes as the commercial efforts get more traction -- so the computers tell the hedge fund they should go long.

Analyst Coverage

All analysts have optimistic, buy rating and price targets well above current price, except Wedbush analyst who has a "hold". No analyst has a "sell" rating. That's very good!


The company received the expanded approval earlier than the March anticipated PDUFA date. It happened in December 2020.


There are various drugs approved for Multiple Myeloma which is a lethal chronic cancer. Due to the availability of medicines the patients can live longer. They get a cocktail of drugs. That works for a while, then the disease comes back, then a new cocktail is given, and so on... all the drugs will get used... point is, you want to be used earlier and in more patients.

Karyopharm still made about 100M revenue last year, so there's obviously demand despite other drugs. None of the drugs cures the cancer.

The company's goals is obviously to capture more market share. So it worked on expanded indication, so doctors can prescribe it for more patients, and also duration of treatment is longer.


92% of float is owned by institutions obviously foresee a positive future for the company, otherwise they would not be holding. Ian gave another great answer: There are many reasons someone would buy a company like Karyopharm, e.g., they think the company is undervalued and think the company's revenues will increase and it will do more for patients and do better financially and that translated into higher value.

Fortunately Karyopharm's drug works for many kinds of cancers so a lot of their spend is to test the drug in other kinds of cancers, and for combination with other drugs. So studies that show the drug works in combination can prove very lucrative.


Company has already inked partnerships for China, South Korea, Taiwan, Australia and other countries in that region, Israel, Palestinian Authority, Canada. Europe and Japan, coming up.


This is a good time in my opinion for a Big Pharma which already has the infrastructure to buy Karyopharm out. A few billion dollars is peanuts for a Big Pharma.


1. EMA conditional approval based on STORM data

2. EMA submission of BOSTON study data (Type II variation)

3. Increased U.S. XPOVIO sales following expanded FDA approval in multiple myeloma

4. SIENDO Phase 3 study fully enrolled and topline data announced

5. EMA expanded approval based on BOSTON study

6. Initiation of Phase 3 study evaluating XPOVIO + pomalidomide in patients with multiple myeloma

7. Initiation of Phase 2 study evaluating XPOVIO + pembrolizumab in patients with metastatic melanoma

8. Additional combination data with XPOVIO and other standard of care anti-cancer drugs to be presented at key medical meetings

9. Continued, increased U.S. XPOVIO sales


§ KPTI seems to have a lot going for it including a very rich pipeline addressing various diseases including multiple myeloma which is a common type of deadly blood cancer. This is a very informative paragraph about Karyopharm:

In July 2019, the US Food and Drug Administration (FDA) approved selinexor (XPOVIO®) in combination with low-dose dexamethasone for the treatment of relapsed/refractory multiple myeloma (rrMM) and in June 2020 approved selinexor (XPOVIO®) as a single-agent for the treatment of relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL). In December 2020, selinexor (XPOVIO®) also received FDA approval as a combination treatment for multiple myeloma after at least one prior therapy. Selinexor (XPOVIO®) is so far the first and only oral SINE compound approved by the FDA and is the first drug approved for the treatment of both MM and DLBCL. Selinexor (XPOVIO®) is also being evaluated in several other mid-and later-phase clinical trials across multiple solid tumor indications, including liposarcoma and endometrial cancer...

and so on-- read full text here: which is the announcement for:

Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA

"rrMM still remains an incurable disease and we are excited that more patients may have access to ATG-010 earlier in the course of their treatment.

§ Last quarterly results

Karyopharm Q4 topline shines, expects XPOVIO sales growth

Revenues: $35.1M (+93.9%); Xpovio Sales: $20M; License and other revenue: $14.8M.

Q1 Outlook: Expects XPOVIO sales to return to growth beginning in the first quarter of 2021.

Cash, cash equivalents, restricted cash and investments as of December 31, 2020 totaled $276.7M.

The company said that the clinical development of XPOVIO in solid tumor indications continues to advance, with top-line data from the Phase 3 SIENDO study in endometrial cancer expected in the second half of 2021.

§ (Feb 2021) H.C. Wainwright Thinks Karyopharm Therapeutics’ Stock is Going to Recover and has price target of $49 and Buy rating.

§ KPTI sitting atop Barclay's M&A list (Dec 2020) Barclay's has a list of candidates for M&A and Karyopharm is the first one on the list with average share price of $60. Barclay's current price target is $31.

§ Jefferies TV segment. Ripe for short squeeze... KPTI has very high short interest and strong fundamentals.

"It's a product story. There's revenue here. It's an oncology company launching drugs into a pretty big market. They're looking for earlier lines therapy etc. etc. - so there is something here to back up the valuation unless so many high flyers that are dream stocks. KPTI has real revenue and earnings and real pipeline... launching during Covid was hard for all companies... but it's interesting anyway."


I was feeling uncomfortable about VYNE over the weekend because I remembered what happened to Arena after approval of Belviq and weak sales. What worries me in the short term is if the pandemic drags on and scrips don't get traction, and the hedgies see that because they have access to weekly sales data and we don't, they could smell blood and attack VYNE like they attacked ARNA, which is easier to do now that the stock is 8 something instead of 1 or 2 something.

So I thought about this a lot. I like VYNE's science, potential market and they have cash. So did Arena, but VYNE's management is incomparable to Arena's back then, which sucked (talking about 2012 to 2017, 5 painful years that some of you remember.

So I chickened out and sold most of my shares at a loss today. I have a few shares to keep an eye on it, and I'll follow the company out of interest, and when prescriptions go up and pandemic goes down, I can get back in. The risk is mine. Maybe it'll take off by then, but that's a choice I made so I live with the consequence :-)

Karyopharm Therapeutics (KPTI)

I've also been following KPTI closely and my liking for the company and the stock's characteristics grew. So I picked up some KPTI today. It's a Massachusetts company focusing on treatments of cancer (e.g. multiple myeloma) and other diseases.

§ Average analyst target: $30

§ Current price: $15

§ 94% owned by institutions (I really like this fact)

§ 10% owned by insiders (that's a lot for a small biopharma)

§ 20% short interest (that's huge, which means good news can start a short squeeze)

§ I sold a few calls against some of the shares I bought today. March 17.50 calls were grabbed instantly (probably by the shorts as hedge -- they think the stock may go to $18 in a month).

§ Enterprise value of almost a billion. I've read they could be a takeover target. I can imagine a big pharma moving in for spare change (3 billion).

§ They already have approval and generating revenue (around $100 million last year).

This is what Dr. Vig wrote in his last update:

§ KPTI karyopharm .com selinexor oral drug for multiple myeloma and likely other cancers, already approved for late stage myeloma and will likely get approved for earlier stage myeloma with pdufa march 19,2021, got approval for lymphoma in June 2020, they were testing selinexor for hospitalized covid 19 patients since selinexor has antiviral and anti inflammatory properties, working on liposarcoma and uterine cancer and lung cancer and glioblastoma as well.

As always, do your own research.

Best wishes

Reza Ganjavi

PS --I just share my research, and I do not provide investment advice.